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General introduction 
Papers 
 
This dissertation is based on the following 7 publications: 
 
• Martiny K, Lunde M, Undén M, Dam H, Bech P (2006). The 
lack of sustained effect of bright light, after discontinuation, 
in non-seasonal major depression. Psychol Med 36: 1247-
1252. 
• Martiny K, Lunde M, Undén M, Dam H, Bech P (2009). High 
cortisol awakening response is associated with an impair-
ment of the effect of bright light therapy. Acta Psychiatr 
Scand 120: 196-202. 
• Martiny K, Lunde M, Bech P, Plenge P (2012). A short-term 
double-blind randomized controlled pilot trial with active or 
placebo pindolol in patients treated with venlafaxine for ma-
jor depression. Nord J Psychiatry 66: 147-154. 
• Martiny K, Lunde M, Bech P (2010). Transcranial low voltage 
pulsed electromagnetic fields in patients with treatment-re-
sistant depression Biol Psychiatry 68: 163-169. 
• Martiny K, Refsgaard E, Lund V, Lunde M, Sørensen L, 
Thougaard B, Lindberg L, Bech P (2012). Nine weeks random-
ised trial comparing a chronotherapeutic intervention (wake 
and light therapy) to exercise in major depression. J Clin Psy-
chiatry 73: 1234-1243. 
•  Martiny K, Refsgaard E, Lund V, Lunde M, Sørensen L, 
Thougaard B, Lindberg L, Bech P (2013). The day-to-day 
acute effect of wake therapy in patients with major depres-
sion using the HAM-D6 as primary outcome measure: results 
from a randomised controlled trial. PLoS One 28;8: e67264. 
• Martiny K, Refsgaard E, Lund V, Lunde M, Thougaard B, Lind-
berg L, Bech P (2015). Maintained superiority of chronother-
apeutics vs. exercise in a 20-week randomized follow-up trial 
in major depression. Acta Psychiatr Scand 131: 446-457.  
 
Major depression  
The diagnostic concepts of depression, as described in the DSM-IV 
(now DSM-5) and the ICD-10 classifications (1, 2), are based on al-
gorithms setting rules for counting clinical symptoms assessed 
through an interview with the patient. These symptoms do point 
to an array of underlying neurobiological defects (3). However, 
treatment of individual symptoms of depression does not lead to 
a resolution of the depressive state. Depression is not cured by 
improving sleep by sleep agents, by using stimulants against lack 
of energy, by making the patient exercise for psychomotor retar-
dation, or by comforting a patient suffering from feelings of hope-
lessness. The lack of etiological foundation makes progress, in 
terms of development of treatment methods, difficult. 
Development of new treatment methods have thus relied on a 
combination of clinical observation, neuropsychopharmacology, 
psychology, and psychometric. Rating scales makes it possible to 
assess treatment outcome with high validity and reliability.   
The course of a depressive episode can be depicted as running 
through a number of stages: progression to a major depressive 
episode, varying levels of response to treatment, in some patients 
leading to remission. Remitted patients who develop a new de-
pressive episode in less than four/six months of remission are de-
fined as having a relapse, and patients developing a new depres-
sive episode after more than four/six months of remission are 
defined as having a recurrence. Recovery signifies a continued re-
mission (of more than four/six months). These timeframes de-
pending on definition (4, 5). The risk of a new episode increases 
with every new episode and depression is, by nature, a recurrent 
disorder (6).  
The use of antidepressants is now a standard for moderate or se-
vere depression. Onset of action is often slow for those who re-
spond and often several months pass before remission is 
achieved. In a substantial proportion of patients remission is only 
achieved after several changes in medication, therapies and set-
tings (7), and approximately 30 % of patients will not obtain re-
mission (8), thus being treatment resistant. The risk of suicide in-
creases with time spent in depression (9, 10). Strategies to 
improve outcome include: optimizing antidepressant drug treat-
ment, combination strategies, or augmentation strategies. Opti-
mizing antidepressant drug treatment includes enhancing treat-
ment adherence, ensuring adequate dosage, ensuring adequate 
duration of antidepressant treatment, or switching to an antide-
pressant with another pharmacologically profile. In patients 
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started on an antidepressant and showing no improvement after 
a few weeks of treatment (11) a change of therapy should be con-
sidered (12). Combination strategies involve the use of two anti-
depressant medications, typically of different classes. Augmenta-
tion strategies involves the addition of a second drug or non-drug 
therapy to existing antidepressant therapy such as lithium, thy-
roid hormone or exercise (13, 14). 
 
Available antidepressant treatment 
options 
Since the introduction of electro convulsive treatment (ECT) in 
the 1930’s and the development of tricyclic antidepressant drugs 
in the 1950’s, depression has been an illness that we do consider 
treatable both by medications. Antidepressants were initially only 
considered useful for a very small minority of patients (15). Since 
the 1950´s several classes of antidepressants have been intro-
duced. The overall efficacy has probably not increased since the 
tricyclic antidepressants were marketed (16), but side effect pro-
files have changed and toxicity is reduced.  
As remission is often difficult to achieve, the use of combination 
and augmentation strategies with antidepressants and other 
drugs is widely used, even though the evidence for many combi-
nations is sparse (17, 18). Combination treatment and drug aug-
mentation carry a risk of more side effects, are expensive for the 
patient and society, often require more specialized settings, and 
thus makes treatment more costly. Most importantly, they are of-
ten not adequate to secure remission. 
The last decade or more has seen a great surge of research into 
psychological therapies, mainly concerning cognitive behavioural 
therapy (CBT), that has been shown to be efficacious alone and 
when used as an augmenting therapy in combination with antide-
pressants (19). Research into non-drug augmentation strategies 
has been sparse. 
 
Experimental treatments 
Due to the low efficacy of existing antidepressant therapies a 
number of experimental therapies have been tested. These can 
be divided into pharmacological, psychological, chonotherapeutic, 
medical devices, and physical therapies. Experimental psychologi-
cal therapies are not touched further upon. The list below high-
lights the experimental methods where some research has been 
done, each supplied with a key reference.  
Pharmacological: Pindolol (20), Thyroid hormones (21), Methyl-
folate (22), Omega3 fatty acids (23), Precursors of neurotransmit-
ters (24, 25), Modafinil (26), Psychostimulants (27), Hypericum 
(28, 29).  
Chonotherapeutic: Sleep deprivation (30, 31), Light therapy (32), 
Dawn-Dusk-Stimulation (DDS), (33), Sleep Phase Advance (34), 
Sleep time stabilisation (35, 36), Melatonin (37). 
Medical devices: Repetitive Transcranial Magnetic Stimulation 
(rTMS) (38), Transcranial Direct Current Stimulation (tDCS) (39), 
Vagus Nerve Stimulation (VNS) (40), Pulsed ElectroMagnetic 
Fields (PEMF) (41), Magnetic Seizure Therapy (MST) (42), low in-
tensity negative ion generators (43). 
Physical: Exercise (44), Body Awareness Therapy (BAT) (45), Acu-
puncture (46). 
 
Contents of this thesis 
This thesis is based on four studies using new augmentation mo-
dalities. The four studies investigate, in randomized controlled tri-
als, the efficacy of these augmentation modalities when used in 
combination with antidepressant drugs treatment. The aim was 
thus to induce a larger or faster antidepressant effect. In the in-
cluded studies we have investigated the effects of bright light 
therapy (bright versus dim light therapy), the beta-blocker pindo-
lol (active pindolol versus placebo), weak pulsating electromag-
netic fields (active pemf versus sham), and a chronotherapeutic 
intervention including wake therapy, sleep time stabilisation, and 
sleep hygiene (versus exercise).  
Background information is described in separate chapters for 
each study. Directions for the use of these augmentation meth-
ods and ideas for further development are addressed. The pub-
lished papers are included as part of the thesis.  
 
1. Bright Light Study 
Study specifics 
Protocol title: Long term bright light therapy in patients in phar-
macological treatment for major depression: Augmented effect 
and improved quality of life? (original Danish title: ”Langtidslyste-
rapi hos patienter i farmakologisk behandling for major depres-
sion: Hurtigere effekt og bedre livskvalitet?”). 
ClinicalTrials.gov Identifier: not required at the time of publica-
tion.  
Abbreviation in text: “bright light study” 
Principal Investigator Site: Mental Health Centre North Zealand, 
Research Unit, University Hospital of Copenhagen. 
 
This chapter is based on papers published after the PhD 
thesis “adjunctive bright light in nonseasonal major de-
pression”:  
• Martiny K, Lunde M, Undén M, Dam H, Bech P (2006). The 
lack of sustained effect of bright light, after discontinuation, 
in non-seasonal major depression. Psychol Med 36: 1247-
1252. 
• Martiny K, Lunde M, Undén M, Dam H, Bech P (2009). High 
cortisol awakening response is associated with an impair-
ment of the effect of bright light therapy. Acta Psychiatr 
Scand 120: 196-202. 
 
Introduction 
The bright light study investigated the use of bright white light to 
augment antidepressant drug therapy in patients with a major de-
pressive episode.  
Light is ubiquitous and linked to our most important sense, vision. 
We know that light has been used in medicine for at least a thou-
sand years to treat different medical conditions such as melan-
cholia or lethargy (31, 47) and hospitals were built to secure max-
imum daylight for patients staying there: “ The aspect of a site, 
which will determine that of the buildings, should, wherever 
there is a choice in the matter, be such as to command the great-
est amount of sunlight at all seasons.” (48). Niels Ryberg Finsen 
was awarded the Nobel Prize in 1903 for the use of light to treat 
lupus vulgaris (49) and light is still used as a treatment option in 
dermatology (and sunlight feared due to a risk of skin cancers). 
From animal research it has been known for decades that dosage 
and timing of light has a profound impact on the regulation of a 
number of biological rhythms including reproduction and sleep 
(50), and in the 1980s it was discovered that in humans, like in an-
imals, the synthesis of melatonin could be suppressed by light 
(51), and that light in this way induced adjustments of the timing 
of the melatonin cycle that informs the brain about night time 
and season (52). Light thus entrains (entrainment = the synchro-
nization of a self-sustaining oscillation such as sleep by a forcing 
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oscillation such as light) the timing of sleep (see figure 1.1). Hu-
mans isolated in dim light conditions have a circadian “free run-
ning” period of approx. 24.18 hours and sufficient natural or ap-
propriate indoor light is necessary to properly entrain the human 
sleep-wake cycle to the 24 hour day (53) and prevent drifting of 
the sleep-wake cycle. The solar day is built into our physiology as 
“clock genes”, present in most of the cells of the body (54), and 
manifesting their own endogenous circadian rhythm under influ-
ence of the suprachiasmatic nuclei (SCN), the biological clock. As 
far as we know the impact of light on human physiology is only 
mediated through the retina. The classical view of the central pro-
jections that transmit the light signal from the retina, and there is 
probably a clock in the retina itself gating light input (55, 56), is 
via the retino-hypothalamic tract (RHT) that directly impact on 
the SCN (57, 58). From the SCN the light signal is mediated 
through the paraventricular nucleus of the hypothalamus (PVN), 
via the intermediolateral nucleus of the spinal cord (IML), to the 
superior cervical ganglion (SCG) and finally to the pineal gland 
where light signals inhibit melatonin synthesis. The SCN generates 
the melatonin rhythm and melatonin itself feeds back to the SCN 
acting through M1 and M2 receptors (59, 60). 
Figure 1.1. Schematic drawing to show entrainment of sleep and 
core body temperature 
  
Circadian Sleep-Wake Rhythms 
 
 
Redrawn with permission from Anna Wirz-Justice, Centre for 
Chronobiology University of Basel                                                                                        
 
The discovery of an unique, primarily non-visual, photoreceptor, 
the intrinsically photosensitive retinal ganglion cells (ipRGC) in the 
human retina in 2000 (61), with a peak spectral sensitivity around 
480 nm (blue wavelength) (62), and elucidation of the newly 
found pathways by which light influences the circadian and other 
systems, mainly by this non-visual input (63, 64, 65), has, how-
ever, given us a fuller understanding of the pathways by which 
the antidepressant effect of light might work. In the mouse, mel-
anopsin containing photoreceptors project to a widespread area 
of the brain (66) other than the SCN, namely the intergeniculate 
leaflet (IGL), the raphe nuclei (RN), the olivary pretectal nucleus  
(OPN), the ventral division of the lateral geniculate nucleus (LGv), 
the preoptic area, and a number of other brain areas known to be 
related to the circadian system (67, 68). Recently a rhythm gener-
ating clock has been detected in the neocortex of the rat pointing 
to primary (SCN) and secondary time keepers within the brain 
(69), and a hypothesis has been proposed, based on animal and 
human translational research, that circadian rhythms in different 
parts of the brain might be out of synchrony in patients with de-
pression (70, 71). Until recently, light was believed to work solely 
through the circadian system but new animal research suggests 
that irregular light schedules can affect mood and learning with-
out any major disruptions in circadian rhythms or sleep (72). This 
has been termed the “direct pathway” in contrast to the “indirect 
pathway”. In support of the “direct pathway” it has been found 
that light is able to affect human mood and alertness acutely 
within hours (73, 74).  
Light has been found to impact regulation of neural circuits and 
neurotransmitter function. Fisher et al (75) found that three 
weeks of bright light significantly negatively affected the threat-
related reactivity in corticolimbic circuits that is modulated by 
serotonin. Lam et al (76) found that tryptofan depletion in SAD 
patients successfully treated with bright light therapy induced re-
lapse also pointing to a serotonergic mechanism behind the anti-
depressant effect of light. Finally Carlson et al (77) found seasonal 
variation of monoamines post mortem and Lambert et al (78) 
found that turnover of serotonin by the brain was lowest in win-
ter and with a relation between serotonin production and the du-
ration of bright sunlight.  
The clinical description of Seasonal Affective Disorder (SAD) and 
the theoretical analogy with hamster hibernation cycles led to the 
development of bright light treatment in the early 1980s (79, 80, 
81). SAD is characterized by repeated seasonal depressions, al-
most exclusively in the winter period (winter depressions), and in 
a majority of patients associated with atypical features such as in-
creased need for sleep, weight gain, and carbohydrate craving 
(82).  Three main hypotheses for the antidepressant effect of light 
in SAD have been put forward:  
1. The phase–shift hypothesis proposes that the shorter days of 
winter cause a circadian phase delay of melatonin secretion rela-
tive to the sleep-wake cycle. Sleep is also delayed to some degree 
but there is a Phase Angle Difference (PAD= time interval be-
tween two circadian markers) between melatonin and sleep 
rhythm. Bright light treatment corrects this abnormality (83, 84) 
by phase advancing the circadian rhythm of melatonin, leading to 
a normalization of the PAD, and resulting in an antidepressant ef-
fect. The description of the ability of light to phase advance the 
sleep-wake cycle and other rhythms when applied in the morning, 
and to phase delay when administered in the evening results in a 
human “phase response curve” (PRC = describing a phase ad-
vance or a phase delay effect of light on the circadian system as a 
function of the time of administration) to light (85,86). Research-
ers of the phase-shift hypothesis believe that the most important 
issue is to correct the Phase Angle Difference (PAD) between Dim 
Light Melatonin Onset (DLMO= the time point in the evening 
when melatonin production rises in dim light conditions, used as 
a marker for assessing the circadian rhythm) and midsleep (87). 
The normal PAD is supposed to be 6 hours, e.g. a 6-hour interval 
between the DLMO and midsleep.  
Results from later studies have not uniformly supported this hy-
pothesis, but maybe these studies did not produce sufficiently 
large phase advances (88) to test the hypothesis. However, in the 
study by Terman et al (89) the magnitude of antidepressant re-
sponse to morning (but not evening) bright light therapy was cor-
related to the degree of phase advance of melatonin onset 
(DLMO) relative to sleep, and thus resulting in a change in PAD. 
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As a clinical applicable rule these authors recommend timing of 
bright light therapy at 8.5 hours after DLMO or alternatively 2.5 
hours after sleep midpoint used as a proxy for DLMO for greatest 
antidepressant effect. A refinement of the therapeutic timing of 
light for a given patient was introduced by the use of the Morn-
ingness-Eveningness (MEQ = questionnaire assessing morning- 
and eveningness) score to establish individual optimal timing for 
light treatment (90). The  phase-shift hypothesis is furthermore in 
agreement with clinical observation and research showing a  pow-
erful positive or deleterious effect on mood of a phase-advance 
or a phase-delay of the sleep-wake cycle in patients with depres-
sion (91).  
2. The photoperiod hypothesis propose that a lengthening of the 
daily photoperiod by administering bright light in the morning 
and in the evening (92) would alleviate depression by simulating 
longer photoperiods as in the summer.  
3. The photon-counting hypothesis claiming that SAD develops 
due to too low levels of light in wintertime and that supplement-
ing bright light corrects this unbalance (93). 
The history of light treatment has been covered in several text-
books (94, 95, 96, 31). In Denmark psychiatrist Henrik Dam was 
probably the first psychiatrist to seriously acknowledge light as a 
treatment modality in psychiatry and to incorporate it into psychi-
atric research and practice (97, 98). At the time when this study 
was planned, bright light therapy was well investigated as a treat-
ment for seasonal depression, but only few studies had examined 
the effect in non-seasonal depression, even though non-seasonal 
mood disorders had for some time been known to harbour a 
number of circadian and seasonal dysfunctions (99).  
In Denmark, situated at latitude 56 degrees and with an abun-
dance of cloudy misty weather, sunlight is scarce in winter (100). 
As a consequence of rainy and misty weather with low light lev-
els, people tend to stay indoors, thus further reducing individual 
light exposure. Whereas indoor light intensities seldom reach 
above 100-300 lux, outdoor light intensities are often above 
2000-3000 lux, even on cloudy days, and reach more than 50.000 
lux on many days. The entraining effect of light is responsible for 
humans staying in tune with the astronomical day, sleeping at 
night and being awake during the day, and indoor lighting levels is 
often inadequate to entrain the sleep-wake cycle.  
Since the seminal paper by Rosenthal et al in 1984 (79), a large 
number of trials have been carried out investigating the efficacy 
of bright light treatment in a number of conditions. The research 
on light in humans first focused on seasonal depression, including 
the stability of the SAD construct (101) and the timing and dosage 
of light, and later non-seasonal depression. The interest into the 
biological effects of light has since broadened into basic neuro-
physiology, visual retinal function (102), retinal photosensitive 
ganglion cells (62), the pathways from the retina to the SCN and 
beyond (103), interaction with and function of the pineal gland 
(104), central and peripheral clock genes (105), cortisol (106), and 
sleep (107). Light applications have also been tested in a number 
of psychiatric and somatic conditions such as eating disorders 
(108), obesity (109), circadian sleep disturbances (110), depres-
sion during pregnancy and postpartum (111, 112), shift work dis-
tress (113), and visual impairment (114). Newer areas are the im-
pact of light on working in space (115), phase delay induced by 
blue-backlight LED computer screens (116), and reproduction 
(117). Research has also expanded to architecture focusing on 
how to develop the best artificial lighting to complement natural 
daylight (118). For the purpose of this thesis only data concerned 
with the impact of bright light on depression is touched upon.  
Recent reviews of clinical trials investigating the antidepressant 
effect of bright light have established an antidepressant effect in 
both seasonal and nonseasonal depression (119,120, 32, 121). 
The impact of bright light on depression symptoms has now been 
shown to be fast, within hours (73), and clinically relevant im-
provement sets in quickly within days (122), and the treatment is 
well tolerated (123).  
At the time when this study was started, the evidence base for 
non-seasonal depression was weaker than for seasonal depres-
sion even though the first light study ever performed, by Kripke 
and co-workers in 1983, was in non-seasonal depression (124). 
That bright light administrated during winter would alleviate sea-
sonal depression seemed to have a theoretical basis but what 
would be the rationale for an effect of bright light in non-seasonal 
depression:  
1. We hypothesised that light would have a general antidepres-
sant effect across diagnostic subgroups, corresponding to what 
we would now call a direct effect of light on mood and alertness 
independent off changes in the circadian system and that patients 
with depression might have too low ambient indoor light levels in 
the winter (and maybe in summer depending on a variety of fac-
tors such as window glazing and size, and geographical orienta-
tion of rooms etc.).   
2. Following the photon-count hypothesis, we predicted that pa-
tients with manifest depression probably received lower light lev-
els due to a tendency to stay indoors, this caused by core depres-
sion symptoms such as lack of motivation and lack of energy and 
also by accompanying anxiety, and with resultant phase delayed 
sleep (eveningness) (125, 126). These patients would have less 
opportunity to get natural light in the morning where the antide-
pressant effect would be largest. 
For some individuals, therefore, the light thresholds for maintain-
ing well-being might not be reached in wintertime (or even sum-
mer time) thus worsening a pre-existing depression.  
3. Seasonality is prevalent both in the general population, also in 
Denmark (127, 98), and in depressed patients, confirmed in our 
previous work (123) and later by others (128). Therefore we be-
lieved that even in non-seasonal depressed patients there would 
be some degree of seasonality and that these patients would ex-
hibit a phase delayed melatonin rhythm and according to the 
phase–shift hypothesis would benefit from morning bright light 
therapy. Investigations have shown that during wintertime, pa-
tients with SAD have a reduced retinal rod sensitivity, as meas-
ured by photopic electroretinogram (ERG) luminance response 
(129), later confirmed and reviewed (102, 130), we believed this 
to apply also to seasonality in non-seasonal depression. It must be 
emphasised that the concept of a distinct seasonal depression 
type (=SAD) was not supported by the DSM-IV and is not sup-
ported by the DSM-5 either, where seasonality is a specifier to re-
current major depressive disorder.    
4. In patients without any seasonality we considered that habitual 
low light exposure might lead to an inadequate entrainment of 
the sleep-wake cycle (free running) causing gradual phase delay 
of the sleep-wake cycle which is known to worsen depression 
(91).  
Thus, in summary, we expected that low light levels and temporal 
misalignment of light caused by season, low ambient indoor light 
levels, behavioural retreat, phase delayed rhythms, and de-
creased retinal sensitivity to light, would have contributed to the 
development of a depressive episode and that light working 
through direct and indirect pathways would act as an antidepres-
sant.  
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Methods and materials 
A detailed description of the study is given in the supplementum 
covering the PhD thesis (123).  Patients were allocated from gen-
eral practitioners and specialist psychiatric practices and assessed 
at the Research Unit at Mental Health Centre North Zealand and 
at a psychiatric research unit. Patients were randomised, after a 
computer generated random list, into either bright light treat-
ment or dim red light treatment with a block size of four, and all 
patients were started on sertraline in a 50 mg daily dosage. Pa-
tients were treated daily with bright or dim light for five weeks 
and then followed for further four weeks, to assess effects of 
stopping light treatment. The light treatment was taken in the 
morning, the bright white light for one hour daily, and the dim 
red light treatment for 30 minutes. The bright light box, used in 
other light studies (SMIFA) (122), was delivered to the patients for 
daily treatment at home. The illuminating surface measured 61 
cm in width and 41 cm in height and the light box emitted 10’000 
lux at a distance of 40 cm with a colour temperature of 5500 K 
(blue-white). For the dim light condition the same light boxes 
were used with a red transparent folio inserted between the fluo-
rescent light fixtures and the diffusing screen, and the intensity 
was reduced electronically to an output of 50 lux at 40 cm dis-
tance. Patients were given oral and written instructions on how to 
take light and were informed that it was not known which colour 
of light was most effective. To attain blinding for the assessors, an 
external secretary delivered light boxes to the patients. Code let-
ters were transferred to opaque sealed envelopes and delivered 
to the patients with instructions not to reveal group assignment 
to assessors. The study was monitored (Norma A/S) and approved 
by the Regional Scientific Ethical Committees and the Danish 
Medicines Agency and the Danish Data Committee. All patients 
were assessed at baseline and weekly with depression scales, 
sleep logs, a side effect scale, light timing diary, and medication 
logs, for six weeks, with a final assessment after an additional 
three weeks. Both light conditions were stopped after five weeks 
and in the following four weeks the sertraline dosage could be in-
creased to a maximum of 150 mg daily according to patients’ con-
dition.  
The primary protocol stated outcome was difference in improve-
ment between groups. The primary outcome measure was re-
sponse (reduction in baseline depression scores of 50 % or more) 
and remission rates (a final score of less than 8) both based on 
the HAM-D17 scale and assessed after five weeks of treatment. Di-
agnosis of major depression was confirmed at baseline by use of 
the M.I.N.I. instrument (131). The SIGH-SAD scale was included to 
cover seasonal symptoms (132). 
Saliva cortisol were collected at awakening, and after 20, 40 and 
60 minutes as described by Pruessner et al (133) before start of 
the study, at week five, and at week nine to determine cortisol 
awakening profiles (CAR).   
Results  
In all, 102 patients were included in the study. Depression scores 
decreased substantially in both groups, but most in the bright 
light treated group. From week one and on all following assess-
ments till week five there was a statistically significant better out-
come in the bright light treated group, resulting at week five in re-
sponse rates of 66.7 % versus 40.7 % and remission rates of 
41.7 % versus 14.8 % in the bright versus the dim light treated 
group. Survival analysis showed a statistically significant higher 
response rate (χ2 = 9.6, p = 0.002) and higher remission rate for 
the whole five weeks study period (χ2 = 12.5, p = 0.0004) for the 
bright versus the dim light treated group.  
At week nine (after light treatment had been stopped for four 
weeks) the results showed a response rate of 79.2 % versus 
75.9 % and a remission rate of 60.4 % versus 55.6 % in the bright 
versus dim light treated group. The difference in depression 
scores seen at week five, favouring the bright-light-treated group, 
thus disappeared gradually in the four-week follow-up period, 
where antidepressant drug dosage could be adjusted, resulting in 
similar end-point scores (134).  
In all, 63 patients collected cortisol saliva samples at baseline and 
at week five. The CAR value was calculated as the area under the 
curve (AUC) of cortisol concentrations plotted against time ac-
cording to Pruessner et al (135). In this thesis, only the AUCI data 
are presented (area under the curve for the increase in cortisol 
concentration in relation to baseline).  Results showed that pa-
tients responded differentially to light treatment according to 
their CAR levels (dichotomized to high or low about the mean). 
Thus, in the bright light group HAM-D17 scores were reduced by 
15.7 (4.2) points for patients with a low CAR (below mean), and 
11.4 (4.8) points for patients with a high CAR (above mean) from 
baseline to week five. In the dim light group the corresponding 
values were 11.1 (5.2) for patients with a low CAR and 11.3 (5.3) 
for patients with a high CAR (see figure 1.2).  This interaction be-
tween CAR and treatment group was statistically significant (p = 
0.006), (136).    
Correspondingly, remission rates at week five were highest in the 
bright light treated group of patients with a low CAR. Thus, in the 
bright light group remission rates were 60.0 % for patients with a 
low CAR (below mean), and 20.0 % for patients with a high CAR 
(above mean). In the dim light group the corresponding rates 
were 19.0 % for patients with a low CAR and 16.7 % for patients 
with a high CAR.  This interaction between CAR and treatment 
group was statistically significant (p = 0.02), (137).  
Figure 1.2 shows HAMD-D17 scores according to treatment group 
and CAR status 
 
 
Discussion 
We could confirm the main hypothesis for the protocol of an ac-
celerating effect of bright light therapy over a period of five 
weeks, but when light treatment was discontinued, the effect was 
lost. This is in accordance with our group’s earlier work in sea-
sonal depression where patients with SAD responding to bright 
light therapy relapsed after stopping light treatment (122). There 
are, however, other possible explanations as to why the differ-
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ence between the dim light and bright light treated groups disap-
peared. Firstly, from a psychometric angle, the obtained scores at 
endpoint are very close to remission. Illustrated by the HAM-D17 
scale, using the remission cut-off at 7 points, the patients treated 
with bright and dim light had a scale score of 8.1 (6.3) versus 8.5 
(5.4) at week nine. Thus the limit of remission is quite close and it 
could be argued that even if the effect of bright light was contin-
ued, the scores in the two groups would converge toward a score 
level not much lower than 7 points. Secondly, the augmenting ef-
fect of bright light treatment could be transient simply because 
the treatment duration was too short. This is comparable with the 
finding that relapse is less likely when stopping medication after 
remission has been reached (138). In order to state with certainty 
that the effect of bright light therapy is transient we would need 
to carry out a study with a prolonged use of bright light therapy 
until remission was reached and then observe the effect of stop-
ping light therapy together with unchanged dosages of medica-
tion. Thirdly, as patients’ responses are highly variable, it is possi-
ble that some patients will have a lasting augmenting effect of 
light therapy after discontinuation whereas others will not. These 
subgroup differences in response to light have not been thor-
oughly investigated. 
The results from the cortisol awakening response showed that 
the subgroup of patients with a high cortisol awakening response 
(CAR) had a significantly lower response to bright light than pa-
tients with a low CAR. This implies that patients with an over-acti-
vated HPA axis are less responsive to the antidepressant effect of 
light. Another important result from the light study was that the 
greatest difference between treatment groups was seen for the 
core depressive symptoms and not for the atypical symptoms 
covered in the SIGH-SAD scale (123) pointing to that the effect of 
light was not primarily working on the seasonal symptoms. Side 
effects of light were rare and compliance with light treatment in 
both groups was high.  
There is no agreement at present on light treatment regimes in 
non-seasonal depression. Personally I would recommend using 
bright light until remission is reached and then tapering it off over 
two to three weeks. This would mean a length of minimum 10 
weeks and maybe longer. The results from the chronos study 
have shown that such long-term light treatment is feasible (139). 
Our results from the cortisol data need confirmation from other 
research groups working with estimation of subgroup responses 
in relation to cortisol.  
The current evidence points to an antidepressant effect of bright 
light treatment in non-seasonal depression even though a recent 
study with bipolar depressed patients failed to find any effect of 
bright light compared to negative air ions (140). Table 1.1 shows 
high quality studies from with-in the last 10 years using bright 
light therapy in non-seasonal depression. This sample displays 
one of the difficulties in assessing evidence in this field: the de-
sign, light conditions and study population differs widely between 
studies.  
 
Table 1.1 Recent RCT bright light studies in non-seasonal unipolar 
depression.  
Author 
 
Benedetti 
2003           
(141) 
Martiny 
2004       
(123) 
Sønder-
gaard           
2006                    
(142)                       
Wirz-
Justice           
2011            
(112)
 
Lieverse                
2011            
(143)   
Dep. type Non- 
seasonal 
Non-sea-
sonal 
Post- 
stroke 
Ante- 
partum 
Non-sea-
sonal 
Design RCT   RCT   RCT                    RCT   RCT   
Active: lux, 
color,  
min/day 
400 
green 
30 
10.000            
white 
60 
10.000           
white 
30 
7.000             
white 
60 
7.500                 
blue 
60 
Placebo: 
lux, color, 
min/day 
Deac-
tivated ion-
generator 
30 
50 
Red 
30 
4.000 
White 
30 
70 
Red 
60 
50 
 Red 
60 
Days of 
study 
14 35 14 35 21 
Medica-
tion 
citalopram sertraline citalopram None TAU* 
Nb. of pt. 30 102 63 27 89 
Blinding  Not 
blinded  
Blinded  Blinded  Blinded  Blinded  
Primary 
outcome 
scale 
Hamilton 
depression 
rating scale 
Hamilton 
depres-
sion rating 
scale 
Hamilton 
depression 
rating scale 
SIGH-
ADS* 
 
Hamilton 
depres-
sion ra-
ting scale 
Result Positive Positive Positive Positive Positive 
*TAU = treatment As Usual, **Structured Interview Guide 
for the Hamilton Depression Rating Scale with atypical de-
pression supplement  
 
2. Pindolol Study 
Study specifics 
Protocol title: pindolol augmentation in venlafaxine treated pa-
tients with major depression (original Danish title: ”En korttids 
dobbeltblind randomiseret undersøgelse af pindolols indflydelse 
på venlafaxins antidepressive effekt”).  
ClinicalTrials.gov Identifier: NCT00159146. Abbreviation in text: 
“pindolol study”.Principal Investigator Site: Mental Health Centre North 
Zealand, Research Unit, University Hospital of Copenhagen. 
 
This chapter is based on the following paper from the 
study: 
• Martiny K, Lunde M, Bech P, Plenge P (2012). A short-
term double-blind randomized controlled pilot trial with 
active or placebo pindolol in patients treated with ven-
lafaxine for major depression. Nord J Psychiatry 66: 147-
154. 
 
Introduction 
This study examined whether the delay in onset of antidepressant 
drug action of four to six weeks could be shortened by augment-
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ing venlafaxine treatment with pindolol in patient with major de-
pression (144). Besides being a beta-blocker with partial beta-ad-
renergic receptor agonist activity, pindolol at the same time 
works as a partial (partial efficacy) antagonist of the presynaptic 
5-ht1a somatodendritic autoreceptors.  
It was artigas et al who in a pilot study from 1994  found that pin-
dolol augmented the antidepressant effect of paroxetine and 
other antidepressants, and formulated the proposed mechanism 
of action (145). By blocking the 5-ht1a autoreceptors in the raphé 
nuclei in the brain stem with pindolol, the initial inhibition of the 
serotonergic neurons, normally seen at the beginning of antide-
pressant treatment with serotonin reuptake inhibitors caused by 
the increase in the extracellular serotonin concentration, would 
be aborted (146). Since the discovery of this mechanism, several 
randomized controlled studies have been performed. The latest 
reviews concluded that pindolol seemed to hasten the response 
to selective serotonin reuptake inhibitors (SSRIs) in depression 
with a timing window circumscribed to the first weeks of treat-
ment, but with some heterogeneity between studies (147, 148, 
17, 149). 
This study was performed by inspiration from Per Plenge and Er-
ling Mellerup, Neuropsychiatric Laboratory Department O, 
Rigshospitalet, based on their publication from 2003 (150) argu-
ing that any acutely working augmenting effect of pindolol should 
work best with paroxetine or venlafaxine due to the ability of 
these drugs to rapidly reach a concentration in water phase giving 
an almost total blockage of the serotonin transporter (151). This 
was in line with our research effort trying to find augmenting or 
acceleration antidepressants agents. To the best of our 
knowledge, no earlier clinical randomized controlled study has ex-
amined the effect of pindolol with other than SSRI antidepres-
sants and we opted for the use of venlafaxine on the above men-
tioned pharmacokinetic grounds and because we would like to 
investigate if the supposed added norepinephrine activity of the 
drug might enhance the augmentation of pindolol. However, 
newer studies have shown that, in humans, the 150 mg daily dos-
age of venlafaxine used in this study probably doesn’t yield a sig-
nificant norepinephrine reuptake inhibitor effect (152).  That the 
antidepressant effect of venlafaxine, in a proper dosage, could be 
augmented by pindolol was suggested by a study from 2000 by 
Béïque et al who found that in rats treated with venlafaxine, addi-
tional treatment with pindolol potentiated the activation of 
postsynaptic 5-HT1A receptors, probably by blocking presynaptic 
somatodendritic 5-HT1A receptors (153). 
In our study, pindolol was used in an extended release formula-
tion, as it was believed to give a more stable receptor blockade 
than with a non-extended release tablet (154, 155). The intention 
was to include patients without current antidepressant medica-
tion as patients in long-term current antidepressant treatment 
might not exhibit an inhibition of the serotonergic presynaptic re-
ceptors, due to habituation (156). Most previous studies has like-
wise preferred drug naïve patients or using a drug wash-out 
phase; and the study by perry et al that included ssri-resistant pa-
tients in current treatment found no efficacy of pindolol augmen-
tation (157). However, due to difficulty in recruiting patients 
without current antidepressant treatment we also allowed inclu-
sion of patients in ongoing antidepressant treatment. Due to 
shortage of additional funding, we chose to terminate inclusion at 
31 patients and not the 50 that was planned in the protocol. The 
number of included patients in the review by whale et al (20) is 
between 21 and 164 and the sample size of our study is thus at 
the very lowest end. The daily dosages of pindolol, in the same re-
view ranged from 10 mg to zero (placebo) whereas we used an 
extended release preparation containing 20 mg pindolol. 
 
Methods and materials 
Patients were included and assessed at two sites, a specialist psy-
chiatric practice in Copenhagen and at the Research Unit at Men-
tal Health Centre North Zealand and were referred from psychiat-
ric specialist practices, general practitioners, and from inpatient 
wards. The study design was a randomised controlled trial with 
double blinding. Patients were randomised into either active pin-
dolol in an extended release formulation containing 20 mg pindo-
lol or a matching placebo pindolol, with a block size of four. Both 
groups were additionally treated with venlafaxine in a 75 mg daily 
dosage for the first five days of the study and venlafaxine in a 150 
mg daily dosage for the remaining 14 days of the study period. 
The total study length was thus 19 days. Assessments were done 
at baseline, day six, day 11 and a final assessment at day 19. 
Blood tests for plasma concentration of pindolol, venlafaxine, and 
its metabolites O -DesmethylVenlafaxine (ODV = metabolite of 
venlafaxine by CYP2D6) and N -DesmethylVenlafaxine (NDV = me-
tabolite of venlafaxine by CYP2C19) were taken at day 12 and 19. 
Diagnosis of major depression was confirmed at baseline by use 
of the M.I.N.I. instrument (131) and at each visit, depression se-
verity, subjective sleep, and side effects were assessed. The pri-
mary outcome was difference in depression severity at endpoint 
between groups. The primary outcome measure were the scores 
on the HAM-D17 scale (158) and the secondary outcome measure 
was the scores on the HAM-D6 subscale (159) or the Bech-Rafael-
sen Melancholia scale (160).  
 
Results 
In all, 31 patients were included. No statistically significant differ-
ence was found between placebo and active pindolol treatment 
during the 19 days’ study period. When examining the patients 
according to their ability to metabolize venlafaxine (v) to o-
desmethylvenlafaxine (odv) calculated by the ratio of plasma o -
desmethylvenlafaxine /venlafaxine (odv/v), we found a statisti-
cally significant interaction with treatment group (f = 7.1, p = 
0.01). Using the odv/v ration as a proxy for metaboliser status we 
concluded that patients with a low odv/v ratio (= poor metabo-
lizer) had a better outcome when treated with pindolol compared 
with placebo than patients with a high odv/v ratio (extensive me-
tabolizer). We could partly confirm earlier findings of a higher 
combined plasma concentration of venlafaxine plus odv in re-
sponders compared to nonresponders (p = 0.04), (161) whereas 
the plasma concentration of venlafaxine or odv alone was not sig-
nificantly different between responders and non-responders. Pin-
dolol concentration did not have any influence on depression out-
come.  
Side effects were mild. One patient left the study due to develop-
ment of asthma, believed to be caused by pindolol. Venlafaxine 
concentration varied greatly on the same drug dosage of ven-
lafaxine 150 mg daily. Thus, at day 19 minimum venlafaxine con-
centrations were 126 nmol/l and maximum concentrations 3912 
nmol/l. Pindolol concentrations varied between 94 and 1819 
nmol/l.  
 
Discussion 
The hypotheses stated in the protocol were “does pindolol aug-
ments antidepressant response” which we could not confirm, and 
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“does the rate of ODV/V, reflecting genotype, influences the ef-
fect of pindolol as an augmenting antidepressant agent” which 
was confirmed.  
As stated in the paper, there are several limitations to the study. 
The interaction found between ODV/V is based on a secondary 
protocol hypothesis, and the study had a small sample size. Fur-
thermore 17 of the included 31 patients were in antidepressant 
treatment at time of inclusion and this might have influenced re-
sults. Due to the small number of patients it is not relevant to 
carry out analyses on the influence of specific drug type on out-
come. Most studies on pindolol augmentation have used drug na-
ïve patients. However, we could not find any discrimination in 
outcome when comparing the group of patients who were in anti-
depressant treatment at inclusion with those that were not. Tim-
ing of pindolol administration could also influence results. In the 
drug naïve patient it might give a better result if pindolol were ad-
ministered before the first dose of antidepressant to prevent neg-
ative feedback. The dosage of pindolol could also be an issue. In 
our study we used a high and extended release formulation of 
pindolol and this could have reduced antidepressant efficacy by 
blocking postsynaptic 5-HT1a receptors. Furthermore, the possi-
ble, perhaps small, norepinephrine activity of venlafaxine might 
also influence results compared to pure serotonergic drugs in an 
unknown direction. 
Rabiner et al in 2004 found a difference in the preferential pindo-
lol occupancy (difference in occupancy between autoreceptor and 
postsynaptic 5-HT1A receptors) between healthy subjects and de-
pressed patients (162). Thus, the preferential occupancy was only 
2.9 % in depressed patients on SSRIs compared to 22.6% in 
healthy volunteers, after a single 10 mg dosage of pindolol, and in 
the paper it is speculated whether this phenomenon is an endo-
phenotype for depression or a result of medication. The mean 
pindolol autoreceptor occupancy, from another experiment in the 
same paper in depressed patients, was only 19.0 % on repeated 
dosage of 15 mg pindolol. Thus, many other factors might influ-
ence the outcome of pindolol augmentation not controlled for in 
this study. We have supplied data in the paper to facilitate com-
parison with studies that have measured plasma concentrations 
of venlafaxine and its metabolites or to use in future studies, in 
order to make possible a replication our finding of a differential 
effect of pindolol in slow and extensive metabolizers. Table 2.1 
shows our own study in comparison with the largest four studies 
in the latest review by Whale et al (20) supplemented by two 
later studies. The outcome is equivocal and even the largest stud-
ies differ in results, suggesting that the uncertainty is not due to a 
type II error. In many of the studies, subgroups of depression 
types and biomarkers have been investigated and no clear results 
have crystallized. In the review by Whale neither baseline depres-
sion severity, placebo-run in, pindolol dosage or antidepressant 
drug type could be associated to any outcome, primarily due to 
too little variation between studies. The preliminary idea by 
Plenge and Mellerup (150) arguing for the use of paroxetine could 
thus not be substantiated in the review by Whale.  
 
Table 2.1. Comparison of high quality RCT studies using pindolol 
as augmentation in depression. 
Author 
 
Zanardi                
1997 
 
(163) 
Tome                     
1997 
 
(164)* 
Geretseg-
ger          
2008 
(165) 
Portella                
2011 
 
(149) 
Martiny                
2012 
 
(144) 
Depres-
sion type 
Uni- and bi-
polar 
Unipolar Uni- and bi-
polar 
Unipolar Uni- and bi-
polar 
Design RCT RCT RCT RCT RCT 
Interven-
tion 
Fluvoxami-
ne 20 mg 
Pindolol 2.5 
mg*3 
Paroxetine 
20 mg 
Pindolol 7.5 
mg 
Paroxetine 
20 mg 
Pindolol 2.5 
mg*3 
Citalopram 
20 mg 
Pindolol 5 
mg*3 
Venlafaxine 
150 mg 
Pindolol re-
tard 20 mg 
Control Fluvoxamine 
20 mg 
Placebo 
Paroxetine 
20 mg 
Placebo 
Paroxetine 
20 mg 
Placebo 
Citalopram 
20 mg  
Placebo  
Venlafaxine 
150 mg 
Placebo 
Placebo 
run-in 
(days) 
7 No infor-
mation 
3  Drug free Not used 
Days of 
study 
42 42 28 42 19 
Nb. of pa-
tients 
155 80 53 30 31 
Blinding  Double 
blind 
No informa-
tion 
No informa-
tion 
No informa-
tion 
Double 
blind 
Outcome  HDRS MADRS HDRS HDRS HDRS 
Result Positive Negative Negative Positive Negative 
HDRS = Hamilton depression rating scale, MADRS = Montgomery 
Åsberg Depression Rating Scale 
*Data retrieved from (148)  
 
3. PEMF Study                                                                                      
Study specifics                                                                                    
Protocol title: pulsed weak electromagnetic fields (PEMF) treatment in pa-
tients with treatment-resistant major depression in on-going antidepres-
sant drug treatment (original Danish title: “PEMF behandling hos patienter 
med behandlingsresistent depression i farmakologisk antidepressiv behan-
dling”). 
ClinicalTrials.gov Identifier: NCT00287703.  
Abbreviation in text: “PEMF study” 
Principal Investigator Site: Mental Health Centre North Zealand, 
Research Unit, University hospital of Copenhagen. 
 
This chapter is based on the following paper from the 
study: 
• Martiny K, Lunde M, Bech P (2010). Transcranial low 
voltage pulsed electromagnetic fields in patients with 
treatment-resistant depression. Biol Psychiatry 68: 163-
169. 
 
Introduction 
This chapter deals with the effect on depression of weak pulsating 
electromagnetic fields (PEMF) as investigated in our randomized 
controlled trial (166). The influence of PEMF on biological systems 
has been the subject of investigation for some time (167), done in 
a number of different plants, species and organ systems going 
from germination of seeds (168) to blood pressure (169). The 
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broad subject “electromagnetic fields” has a long and colourful 
history within science and (science-) fiction (170) often giving a 
connotation of something fantastic and even spiritual. Thus, it is 
important to state that the supposed mechanism of action of 
PEMF is through the induced electrical currents in the brain due 
to a changing electromagnetic field.  
The principle of PEMF, as used in this study, is the following: a 
pulsed current (in mA) generated in a coil creates a time-varying 
magnetic field according to faradays law. In the PEMF system, the 
resultant time-varying magnetic field is imposed on ions and 
charged proteins in the cerebral cortex where it creates a time-
varying electrical field (171). As illustrated in figure 3.1 the in-
duced electrical field is proportional to the changes in currents 
running through the coils.  
Figure 3.1 time relation between current in coils and the resultant 
electromagnetic field. 
 
It is important to note that the electrical field imposed on the cer-
ebral cortex using this technology is very small and amount to ap-
proximately 30 µV/cm at 10 cm from the coil (166). The trans-
membrane electrical potential is approximately -70 mV across a 
cell membrane 5 nm wide equivalent to and electrical gradient of 
1.4 *104 V/cm, and thus very much larger than the PEMF induced 
electrical field. The threshold potential is about -55 mV. Thus, the 
stimulus from the PEMF equipment is fundamentally different 
from, for example, the principle of repetitive Transcranial Mag-
netic Stimulation (TMS) in which potential changes during treat-
ment are just below the threshold for opening of Na+ channels 
and therefore close to being able to elicit action potentials. Rec-
ommended intensity in rTMS is between 90 % and 120 % of the 
motor threshold (172).The pulse patterns of the PEMF generator 
were designed to mimic, in magnitude and frequency, the electri-
cal fields occurring outside nerves and muscles due to their own 
propagation of action potentials. 
There is no evidence that humans can consciously register a 
changing electromagnetic field or the ultra-low electrical currents 
induced by the PEMF technology. However, very low-level, envi-
ronmental-strength electromagnetic fields have been shown to 
have a biological impact in humans (173). In animals, birds can 
detect weak electromagnetic signals and act upon them when 
setting a flying trajectory, and sharks use electrical sensors when 
seeking out prey by being able to sense electrical signals from 
preys heart activity in the range below 5 nV/cm (174, 175) which 
is lower than the calculated PEMF generated electrical field in the 
brain. In animals, the receptor system for weak electromagnetic 
fields has been proposed to be located in specialized cells where 
interaction between the changing electrical field and glycopro-
teins bound to ion channels gates would then mediate an intra-
cellular signal (176). The existence of low electrical field receptors 
in the human brain is, however, debated.  
PEMF stimulation has been shown to cause activation of tyrosine 
kinase related cellular signaling in endothelial cells, glial cells and 
up-regulation of m-RNA for BDNF and angiogenesis (177). Clinical 
studies of PEMF have so far been restricted to non-psychiatric in-
dications such as osteoarthritis (178, 179), microcirculatory ef-
fects (180), neuron growth (181) and others. Currently, in all, 26 
clinical studies are listed on clinicaltrials.gov homepage involving 
the use of PEMF technology with different indications for its use 
(182). 
 
Methods and materials 
Patients were allocated from psychiatric specialist practices, gen-
eral practitioners, psychiatric outpatient departments, a commu-
nity mental health centre, and by use of advertisement (n=2) and 
assessed at the Research Unit at Mental Health Centre North Zea-
land and at a specialist psychiatric practice. Diagnosis of major de-
pression was confirmed at baseline by use of the M.I.N.I. instru-
ment (131). The design was a randomised controlled trial with 
double blinding. Patients were randomised from a computer gen-
erated random number list into either active PEMF treatment or 
sham PEMF treatment with a block size of ten. The sham condi-
tion was obtained by an internal deactivation of the PEMF gener-
ator and was not discernable from the outside. Both the active 
and the sham PEMF were taken for 30 minutes on all weekdays at 
the same psychiatric research unit and specialist psychiatric prac-
tice for five weeks. The PEMF delivery system consisted of a pulse 
generator, receiving 220 V, and providing pulses to the applicator 
constructed as a plastic treatment helmet. The dimensions of the 
Re5 PEMF generator was (width x height x depth) 2.8 x 1.6 x 9.2 
inches. The pulses provided by the generator to the coils in the 
helmet alternate between +50 and – 50 V. The treatment helmet 
incorporated, on the inner side, 2 coils in the anterior and poste-
rior temporal region on both sides and 1 coil in the upper parietal 
region on both sides and 1 coil in the centre of the lower occipital 
region. Thus, in total, 7 coils were connected in parallel with the 
pulse generator. The Re5 PEMF pulse generator powers the coils 
with alternating bipolar square pulses, each lasting 3 milliseconds 
and interspersed by a 12 milliseconds pause, each pulse-sequence 
thus lasting 18 milliseconds (see figure 3.1) , corresponding to a 
pulse frequency of 56 Hz (for comparison cell phones operate in 
GigaHertz frequencies). The rapid change of the current in the 
coils from the pulse generator creates an alternating magnetic 
field with a calculated maximum of 19 Gauss at 0.5 cm from the 
coil and capable of inducing electrical fields in tissue with a mag-
nitude of 2.2 mV/cm at a distance of 0.5 cm from the individual 
coil (41).The imposed electrical field decreases approximately ex-
ponentially with distance and amounts to 30 μV/cm at 10 cm 
from the coil.   
Primary inclusion criteria were current major depression accord-
ing to the DSM-IV system and with a minimum treatment re-
sistance level of three according to Sackheim (183). To assess 
blinding, patients were asked after completion of the study, to in-
dicate which treatment they had been given (active or sham). 
PEMF generators were consecutively numbered by the monitor-
ing company Remedium Aps (184) according to the randomisa-
tion list.  
The study was approved by the Regional Scientific Ethical Com-
mittee, and the Danish Data Committee. All patients were as-
sessed weekly with depression scales, a cognitive speed test 
(AQT), sleep log, side effects scale, and PEMF treatment logs, for 
five weeks. Medication was unaltered during the five weeks study 
period and four weeks prior to inclusion. Primary outcome as 
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stated in the protocol was difference in improvement between 
groups at endpoint. The primary outcome measure was reduction 
in scores on the Hamilton depressions rating scale (HAM-D17) and 
secondary outcomes were response and remission rates based on 
the Hamilton depression rating scale according to the usual crite-
ria.  
 
Results 
In total, 50 patients were included and all entered the statistical 
analysis. The mean duration of current depressive episode was 
31.3 (34.3) months in the active PEMF group and 34.7 (55.0) 
month in the sham treated group; number of previous depressive 
episodes were 6.4 (5.3) and 6.4 (5.5) in respective groups. The 
blinding test, carried out at the final assessment, showed that pa-
tients were not able to determine whether they had received ac-
tive or sham treatment. At inclusion into the study, patients were 
treated with one or more psychotropic drugs: SSRI, SNRI, NaSSA, 
tetracyclic, tricyclic, NaRI, MAO inhibitors, mood stabilizers, anti-
psychotics, and hypnotics. All patients had major depression and 
in a greater proportion with melancholic features. Two patients 
were suffering from bipolar depression, 10 patients had comorbid 
panic disorder, nine had social phobia, and five had agoraphobia. 
No patients had any previous or present psychotic disorders. The 
patients’ treatment expectancy was low with a score around 5.0 
(2.4) in the active treated group and 5.4 (1.7) in the sham treated 
group (0 = no expected improvement, 10 = maximum expected 
improvement). Baseline HAM-D17 scores were 21.1 (4.1) in the 
group treated with active PEMF and 20.9 (3.3) in the group 
treated with sham PEMF treatment. Patients were assessed at 
baseline and weekly for 5 weeks. The active PEMF treated group 
had the largest reduction in depression scores and this reached 
statistical significance from week one and on all the following as-
sessments (p < 0.01). On the HAM-D6 a statistical significance was 
found from week two and on and on the MES from week one. Re-
sponse at endpoint was 61.0 % in the group treated with active 
PEMF and 12.9 % in the sham treated group (p < 0.01). Remission 
was obtained in 33.9 % in the active group and 4.1 % in the sham 
treated group (p < 0.05). Side effects were similar between 
groups and were mild. A further analysis from the same study fo-
cusing on self-assessment (HAM-D6 self-rating, WHO-5 Quality of 
life and UKU side effect) found comparable results (185).  
 
Discussion 
The hypotheses stated in the protocol “does active PEMF treat-
ment reduce depression scores more than sham PEMF” and 
“does active PEMF treatment increase response and remission 
rates more than sham PEMF” were both confirmed. The placebo 
response in the sham treated group was very low, as seen in clini-
cal studies in patients with treatment resistant depression. The 
present study was designed to investigate whether any signal of 
effect could be found for the PEMF treatment and was not de-
signed to estimate the full magnitude of antidepressant effect. 
With the obtained endpoint remission rates of 33.9 % in the ac-
tive PEMF treated group and 4.1 % in the sham treated group af-
ter 5 weeks of therapy it would be interesting to investigate 
whether a longer treatment period would induce larger remission 
rates. In the latest PEMF study, in patients with depression, inves-
tigators used a design with one versus two treatments per day, 
and found remission rates after 8 weeks of therapy of 73.5 % ver-
sus 67.7 % (186).  
The mechanism by which the PEMF treatment works as an antide-
pressant augmenter is unknown. Even though we know some of 
the biological effects of PEMF on living tissue it is premature to 
suggest any specific antidepressant effect. The challenge will be 
to find out how such weak alternating electrical currents are able 
to translate into a large antidepressant effect. Brain imaging stud-
ies, in a sham controlled trial design, should be able to find 
changes in brain functioning in areas believed to be of interest as 
mediators of antidepressant effect. This will require the use of 
different neuroimaging techniques and biomarkers. The exact 
molecular effect will probably require neurophysiological studies 
of candidate receptors or intracellular messengers; this is cur-
rently being investigated by Professor Steen Dissing and his 
group. This group hypothesizes that activation of brain endothe-
lial cells (blood brain barrier) contributes to the beneficial effects 
of PEMF.  Recently researchers have focused on the relation be-
tween the pulsed nature of electrical brain stimulation therapies, 
including PEMF and their potential to entrain brain oscillatory ac-
tivity (187). Perhaps the zeitgeber ability of light and the electrical 
oscillation from the PEMF generator both works through entrain-
ment of brain circuitry.  
As mentioned in the general introduction to this thesis, a number 
of noninvasive brain stimulation (NIBS) based therapies have 
been developed for the treatment of depression: ElectroConvul-
sive Treatment (ECT), Magnetic Seizure Therapy (MST), repetitive 
and synchronized Transcranial Magnetic Stimulation (rTMS and 
sTMS), Direct Current Stimulation (tDCS), and Vagus Nerve Stimu-
lation (VNS) (188, 189). ECT is a well-established method with 
high efficacy, but with a tendency to relapse after end of treat-
ment and cognitive transient side effects.  MST probably has the 
same efficacy as ECT and maybe with less cognitive side effect 
but, like ECT, requires anesthesia. TDCS has only been used in a 
few studies, some showing promising effect and low side effect 
rate but the real efficacy and indication for this treatment re-
mains uncertain. rTMS has been extensively investigated and re-
cent reviews has found a moderate efficacy and low side effects 
but rTMS requires daily or frequent treatments in hospital set-
tings.  sTMS where the magnetic stimulus is synchronized to the 
individual patient’s alpha waves is purely experimental. The effi-
cacy of VNS is unsettled, the antidepressant effect might be de-
layed until one year, and stimulus intensity and properties of the 
implanted stimulator including the mechanical contact between 
the electrical wire and the vagal nerve is still under development. 
The PEMF technology is simple, easy to use, the latest study used 
a home stimulation regime, and thus requires no assistance, and 
side effects were very mild. More randomised controlled trials 
needs to be done, by other research groups, to establish efficacy 
in different subtypes of depression and for maintenance or re-
lapse prevention.         
Table 3.1 shows our own study in comparison with different NIBS 
therapy studies using, ECT, Transcranial Magnetic stimulation, Di-
rect Current Stimulation, Magnetic Seizure Therapy, and Vagus 
Nerve Stimulation. 
These studies were designed as sham controlled RCT’s apart from 
the VNS study using a dose-response design. The stimulus re-
ceived at brain tissue level is difficult to compare as the means of 
delivery are specific for every treatment method.  
 
Table 3.1. RCT studies using NIBS as augmentation in depression. 
Author 
 
Bran-
don 
Klein  
1999 
 (191) 
Loo 
2010 
(192) 
Martiny 
2010 
(166) 
Kayser 
2011 
(193) 
Aaron-
son 
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1984 
(190) 
2013 
(194) 
Therapy ECT TMS tDCS PEMF MST VNS 
Depres-
sion type 
Unipo-
lar 
Uni- and bi-
polar  
Unipo-
lar  
TRD TRD* Chronic  
Design RCT  RCT RCT  RCT  RCT  RCT  
Active in-
terv. 
ECT TMS tDCS PEMF MST 3 inten-
sities 
Active ap-
plicat. 
Bitem-
poral 
Right pre-
frontal 
Left 
DLPFC 
Multifo-
cals 
Twin 
coil 
Implan-
ted VNS 
Frequency 
(Hz) No info. 1 
Contin-
uous 50  100 10-20 
Wave 
form  
Chop-
ped 
sine 
wave 
Mono- or 
biphasic None 
Bipolar 
square 
pulse 
Dampe-
ned co-
sine 
No infor-
mation 
Pulse 
width  No info. 100 µs None 3 ms No info 
130-250 
µs 
Control 
interven 
Sham 
ECT 
Sham TMS Sham 
tDCS 
Sham 
PEMF 
ECT 3 inten-
sities 
Control 
applica-
tion 
Bitem-
poral 
Right pre-
frontal  
Left 
DLPFC 
 
Multifo-
cal 8 co-
ils 
Right 
unilate-
ral  
Implan-
ted VNS 
Medica-
tion 
None Continued Conti-
nued 
Conti-
nued 
Conti-
nued 
Conti-
nued 
Days  28 14 9  35 42 22+28 w 
Nb. of pt. 95 70 35 50 20 331 
Blinding  No info. Rater blind Double 
blind 
Double 
blind 
Open 
label 
Open la-
bel 
Scale HDRS Respons  MADRS HDRS  MADRS IDS-C 
Side eff. No info. No info. Minor  None Minor  No info. 
Result 
 
Active 
ECT bet-
ter 
Active TMS 
better 
No dif-
ference  
Active 
PEMF 
better 
No dif-
ference 
  
High in-
tensity 
best  
HDRS = Hamilton depression rating scale, MADRS = Montgomery 
Åsberg Depression Rating Scale, IDS-C = Inventory of Depressive 
Symptomatology, TRD =Treatment Resistant Depression. 
4. Chronos Study 
Study specifics 
Protocol title: Chronos, the use of chronotherapeutic treatment in 
depression (original Danish title: ”Kan den af søvndeprivation in-
ducerede antidepressive effekt hos patienter med major depres-
sion i duloxetin-behandling vedligeholdes ved hjælp af vedvarende 
stabilisering af døgnrytmen og langtidslysbehandling?”).Clinical-
Trials.gov Identifier: NCT00149110.  
Abbreviation in text: “chronos study” 
Principal Investigator Site: Mental Health Centre North Zealand, 
Research Unit, University Hospital of Copenhagen. 
 
This chapter is based on the following papers from the 
study: 
• Martiny K, Refsgaard E, Lund V, Lunde M, Sørensen L, 
Thougaard B, Lindberg L, Bech P (2012). Nine weeks ran-
domised trial comparing a chronotherapeutic intervention 
(wake and light therapy) to exercise in major depression. J 
Clin Psychiatry 73: 1234-1243. 
• Martiny K, Refsgaard E, Lund V, Lunde M, Sørensen L, 
Thougaard B, Lindberg L, Bech P (2013). The day-to-day 
acute effect of wake therapy in patients with major depres-
sion using the HAM-D6 as primary outcome measure: results 
from a randomised controlled trial. PLoS One 28;8: e67264. 
• Martiny K, Refsgaard E, Lund V, Lunde M, Thougaard B, Lind-
berg L, Bech P (2015). Maintained superiority of chronother-
apeutics vs. exercise in a 20-week randomized follow-up trial 
in major depression. Acta Psychiatr Scand 131: 446-457.  
 
Introduction 
In this thesis, and in our own papers, the term ‘wake therapy’ is 
used in preference to sleep deprivation. Wake therapy when used 
as in the present regime, does not cause a major sleep debt but 
more a rearrangement of the sleep schedule. The practical inspi-
ration to work with wake therapy came from Professor Francesco 
Benedetti and his research group at Hospital San Raffaele in Mi-
lano (195)  who had been working with wake therapy, mainly in 
patients with bipolar depression, for a number of years (196), and 
from the members of the Committee of Chronotherapeutics of 
the International Society for Affective Disorders (ISAD) (197). Our 
chronos research team visited Hospital San Raffaele in Milano in 
2004. We had the opportunity to experience how wake therapy 
was performed, from observing a patient who went through the 
procedure, and confer with Dr. Francesco Benedetti and his staff 
about their experiences with the use wake therapy. In this way 
we learned how to carry out this treatment method. Professor 
Anna Wirz-Justice from Basel, and Professor Francesco Benedetti 
had, in collaboration, developed the protocol used at San Raf-
faele, and this was adopted in a slightly modified version into the 
chronos study. The procedures for the management of wake ther-
apy in this study were thus adopted as they encompass the evi-
dence and experience collected through several decades and in-
clude recent findings from studies combining wake therapy with 
bright light therapy and sleep phase advance.  
The chronos study can be regarded as an extension of the bright 
light study based on a theoretical framework from chronobiology 
and from corresponding chronotherapeutic treatment regimens. 
In the chronos study we added three chronotherapeutic princi-
ples to bright light therapy: wake therapy, sleep phase advance, 
and sleep time stabilisation.  
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The antidepressant effect of sleep deprivation has been known 
for a long time, already mentioned in Johann Christian August 
Heinroths Textbook of Psychiatry from 1818 (198). Sleep depriva-
tion was later mentioned in a case-report from Schulte in 1966 
(199), and in 1973 Pflug investigated sleep deprivation in his Ha-
bilitationsschrift (thesis) (200). Pflug was thus the first to establish 
clinical evidence for an acute antidepressant effect of sleep depri-
vation. Pflug and Tölle wrote extensively on the subject in the fol-
lowing years (35, 201, 202).  Studies and reviews have been pub-
lished by a number of authors from different European countries 
and from the US in the following decades (203, 204, 205, 206, 
207, 208). The great majority of studies, except for an adjuvant 
study using trimipramine, confirmed the acute antidepressant ef-
fect of wake therapy in a major proportion of patients (209), in-
cluding the tendency to relapse after recovery sleep, but also doc-
umented that a subset of patients have a lasting antidepressant 
effect of wake therapy treatment even though this subset is not 
clearly characterized. No clear relation has been found between 
the numbers of wake therapies in a treatment algorithm and out-
come, and studies have used very different number of wake ther-
apies from a single up to more than ten (205). However, in the 
study by Kuhs et al (210) using amitriptyline and repeated PSD, 
the effect of additional nights with partial sleep deprivation was 
only evident after the fourth PSD in weeks 3/4. Total wake ther-
apy (the whole night) is probably more effective that partial wake 
therapy (211). The timing of the partial wake therapy (early or 
late night) is probably not of great importance to effect, however, 
we need more investigation into this topic (212). Patients with bi-
polar illness have been found to have a superior response com-
pared to unipolar depressed patients (213) and switch to mania is 
rare provided bipolar patients are in mood stabilizing drug treat-
ment (214). Diurnal variation (morning worst), and the magnitude 
of daily and day-to-day mood fluctuations, have consistently been 
found to predict a better response to wake therapy (215). Naps in 
the daytime after wake therapy has been found to induce relapse 
in some patients (216). No increase in suicidal ideation has been 
found in relation to wake therapy procedures (217, 218). Nearly 
all patients in clinical studies have been treated in hospital set-
tings with a few exceptions (219, 220). 
The use of wake therapy regimens and the research database is 
described in detail in the manual written by Anna Wirz-Justice, 
Francesco Benedetti and Michael Terman (31) and in the Hand-
book of Clinical Neurology (221).  
Wake therapy has been used continually in psychiatric clinics 
mainly in Germany, Holland and Italy. Wake therapy is recom-
mended in the WFSBP guideline for unipolar depression as an op-
tion for unmedicated depressed patients, or to be started at the 
same time as an antidepressant medication with the goal of accel-
erating the response to medication or to be added as a strategy 
to potentiate an ongoing antidepressant drug therapy (18), and in 
the CANMAT guideline as an adjunctive treatment in the acute 
management of mild to moderate MDD, and with some limited 
support for its use in seasonal, antepartum and postpartum major 
depressive disorder (222).  
Research in chronobiology and chronotherapy for mood disorders 
has increased in recent years. Based on findings, in both animal 
and human research, a clear connection has been found between 
circadian clock disturbance and mood disorders (223, 71). Data 
now suggests disrupted circadian synchronisation within regions 
of the brain itself: circadian transcription of a number of genes is 
out of phase between different brain regions in patients with de-
pression in contrast to normal controls (224). The exact mecha-
nism(s) behind the acute antidepressant action of wake therapy 
and sleep phase advance is not understood. It is proposed to 
work differently from traditional antidepressant drug therapy due 
to the observed very rapid acute effect over hours. Several possi-
bilities have been considered: 
1. Increased activity of the raphe nuclei. From animal research we 
know that the serotonergic activity from the dorsal raphe nuclei 
(DRN) is reduced during REM and slow wave sleep (225). In cats, 
total sleep deprivation (TSD) has been found to increase sero-
tonergic activity from the DRN (recorded through stereotaxically 
implanted electrodes) and found to diminish neuronal inhibition 
produced by administration of a selective 5-HT1A selective agonist 
(226). In the same way, a decreased sensitivity of the inhibitory ef-
fect of citalopram on 5-HT neuronal firing was found in sleep de-
prived rats (227). These findings point to that TSD could also work, 
by decreasing 5-HT1A autoreceptor sensitivity thus enhancing ser-
otonergic transmission.  
The role of the DRN is substantiated by the clinical finding that, se-
lectively waking patient with depression during REM sleep or dur-
ing slow wave sleep phases, elicits an antidepressant response 
(228, 229). Conversely, daytime napping in patients responding to 
sleep deprivation has been found to induce relapse into depression 
and more so if naps were placed in the morning (230). Wake ther-
apy might thus work by a combination of desensitisation of the 5-
HT1A autoreceptor and by removing the dampening effect on the 
DRN by REM and slow wave sleep. 
2. Psychological/placebo mechanisms. It is unlikely that this effect 
can be explained by a psychological effect. No known psychother-
apeutic method has ever shown acute improvement in a few 
hours as seen with wake therapy. Placebo responses are also not 
likely to be of importance, as patients when introduced to wake 
therapy feel that it is counterintuitive as they already have diffi-
culty sleeping.  
3.  Serotonergic, noradrenergic and dopaminergic mechanisms 
might be involved. A number of treatments with 5-HT-related 
treatment modalities have been shown to potentiate wake ther-
apy or prevent relapse after wake therapy:  pindolol, bright light, 
lithium, SSRI’s and TCA antidepressants (231, 232, 233, 234, 210). 
This is substantiated by the finding of a differential response to 
wake therapy from patients with polymorphism within the pro-
moter of the serotonin transporter gene, with a superior re-
sponse seen for homozygotes for the long alleles (235). However, 
one study showed that tryptophan depletion had no effect on re-
sponse to wake therapy, whereas it unexpectedly did prevent re-
lapse after recovery sleep (236). One study investigated the effect 
of a Val/Met polymorphism in the Catechol-O-methyltransfer-
ase (COMT) enzyme. COMT works by inactivating, among other, 
norepinephrine and dopamine. This investigation showed that pa-
tients who were homozygotic for the Val/Val variant had a 
smaller acute antidepressant effect of wake therapy than patients 
who were hetetozygotic (Val/Met) and homozygotic (Met/Met) 
for the Met variant (237). In a SPECT study by Ebert et al (238) 
with sleep deprived depressed patients they found a decrease of 
relative basal ganglia D2 receptor occupancy after TSD in re-
sponders compared to nonresponders. In the study by Gessa et 
al, administration of haloperidol to sleep deprived rats inhibited 
behavioral activation, with shortening of the sleep latency (239). 
These results suggest dopaminergic involvement in the therapeu-
tic action of wake therapy and might explain why antipsychotic 
drugs abolish the effect of wake therapy (240). 
4. Internal coincidence hypothesis. In forced desynchrony proto-
cols the influence of process S (the homeostatic sleep drive) and 
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process C (the circadian drive for arousal) on mood and other var-
iables can be separated by, in a rigid protocol, submitting patients 
to artificial daylength schedules outside the range of entrainment 
of the human circadian system (more than 28 hours or less than 
22 hours). This way the sleep-wake cycle follows the imposed 
daylength but the circadian system will be out of synchrony with 
sleep schedule, resulting in different relationships between the 
two processes.  These investigations have shown that a nonlinear 
interaction between the circadian rhythm and the sleep-wake cy-
cle determines daily patterns of mood, sleepiness, alertness and 
other cognitive symptoms (241). The internal coincidence hypoth-
esis poses that the phase angle (time-misalignment) between the 
sleep-wake cycle and the circadian system (internal desynchrony) 
is causing depression (e.g. is depressogenic). Patients with de-
pression may be sleeping out of alignment with their inner circa-
dian rhythm, like a person with jetlag or shiftwork. Wake therapy 
is thought to function by avoiding sleeping in a depressogenic 
phase (the second half of the night) and by realigning the circa-
dian and the sleep-wake cycle during recovery sleep nights. Thus, 
it is possible that therapies working on synchronising the circa-
dian system with the sleep-wake cycle will also have a correcting 
impact on between-region difference in the brain of clock gene 
expression and in this way influence mood (242). 
5. Sleep-phase-advance. Most wake therapy schedules include a 
slight sleep-phase advance by adjusting the recovery nights to an 
earlier time schedule and maintaining this as long as possible. The 
idea that sleep-phase advance would be an antidepressant comes 
from the work of Tom Wehr and coworkers (243) claiming that 
REM sleep (patients with depression have short REM latency) and 
other circadian rhythms are phase-advanced relative to the sleep-
wake cycle and that correction of this circadian misalignment has 
an antidepressant effect. These finding have been replicated by a 
number of researchers (91, 207). The added benefit of bright light 
therapy, in wake protocols, is probably partly caused by a rein-
forcement of the stability of the sleep-wake cycle with an inbuilt 
sleep phase advance or at least an avoidance of oversleeping.  
6. The S deficiency model. In the two process model of sleep regu-
lation (244) sleep is supposed to be regulated by two processes: 
process S, the need for sleep, a process postulated to be caused 
by the build-up of sleep pressure, for example, a chemical sub-
stance such as adenosine. Process S increases with time spent 
since last slept and is reflected in an increased subsequent 
amount of delta sleep in recordings from recovery sleep after a 
night awake  (245). The other component is process C, the circa-
dian component driven by the central circadian pacemaker in the 
SCN. In the evening, process S is high and coincides with fall in the 
circadian signal for wakefulness, which is mirrored by the increas-
ing melatonin level, and as a result sleep is possible. In the morn-
ing, process S is low due to the time slept, and coincides with a 
rise in the circadian wake signal, and this makes awakening possi-
ble. The S deficiency model poses that the built-up of sleep need 
in depression is insufficient and wake therapy is as an interven-
tion that causes a momentary large increase in sleep need (246). 
7. Resetting of abnormal clock genes. Various clock gene expres-
sions are disturbed in depression and the hypothesis is that wake 
therapy restores them to a normal level, specifically the 
BMAL1/CLOCK genes are supposed to be involved and to interact 
with sleep homeostasis  (247,248 ). 
9. Overarousal hypothesis. Depression can be understood as a 
state of physiological overarousal and in this hypothesis wake 
therapy is supposed to reduce this state. This is based on observa-
tions of higher baseline motor activity in responders to wake 
therapy than in nonresponders (249). This is also supported by 
sleep abnormalities in depressed patients mimicking disturbed 
sleep as seen in stress disorders.     
Brain imaging studies have investigated a number of regions of in-
terest (ROI) for depressive disorders. We would expect changes in 
activity of the anterior cingulate and dorsolateral prefrontal re-
gions and in the connection between these areas, as this have 
been found to correlate with an improvement in depression 
symptoms. In a resting-state fMRI study in healthy subjects by 
Bosch et al (250), it was found that sleep deprivation reduced 
connectivity between posterior cingulate cortex and bilateral an-
terior cingulate cortex and enhanced connectivity between dorsal 
nexus (an area within the dorsal medial prefrontal cortex that 
serves as an intersection point for multiple brain networks) and 
areas in dorsolateral prefrontal cortex suggestive of restoring of a 
dysfunctional brain network.  
The limbic system has been investigated in a few studies. In an 
fMRI study, Clark et al (251) found, in unmedicated depressed pa-
tients, a greater baseline amygdalar perfusion in responders to 
partial sleep deprivation (PSD) than in nonresponders. In the right 
amygdala, perfusion increased in nonresponders and decreased 
in responders after wake therapy compared to baseline whereas 
the left amygdala did not show any significant change between 
baseline and PSD conditions. 
Correspondingly, in a PET study by Wu et al (252) it was shown 
that depressed patients responding to sleep deprivation had 
higher baseline relative metabolic rates in medial prefrontal cor-
tex, ventral anterior cingulate and posterior subcallosal gyrus 
compared to depressed patients who did not respond to sleep 
deprivation, and to normal subjects. After sleep deprivation a de-
crease in metabolic rates was found in the medial prefrontal cor-
tex and frontal pole in patients responding to sleep deprivation. A 
subsequent PET study from the same group found positive corre-
lations (defined as reduced HDRS scores associated with areas 
having reduced relative cerebral glucose metabolism after TSD) in 
the inferior frontal gyrus and inferior frontal/orbital frontal cor-
tex. Negative correlations (defined as reduced HDRS scores asso-
ciated with areas of increased relative cerebral glucose metabo-
lism after TSD) were found in the dorsolateral prefrontal cortex 
(253). An fMRI study in healthy individuals by Gujar et al (254) 
showed that sleep deprivation amplified reactivity in mesolimbic 
reward brain networks in response to pleasure-evoking stimuli.  
Dopamine turnover was discussed by Ebert et al (255) who ar-
gued that administration of psychostimulants decreases limbic 
metabolism similar to what is seen in wake therapy responders. 
Benedetti et al (256) have performed single proton MRI investiga-
tions in patients with depression undergoing sleep deprivation. 
They investigated the excitatory neurotransmitter glutamate, 
which is believed to play a role in the pathophysiology and treat-
ment of mood disorders, in bipolar depressed patients who were 
treated with wake therapy. Changes in the brain glutamine/crea-
tine ratio followed a general trend toward decrease, with individ-
ual variability that correlated with improvement of depression 
(257). Benedetti et al (258) performed another MRI study in bipo-
lar depressed patients doing wake therapy and tested moral va-
lence decision at four time points before and after wake therapy. 
The results from the MRI studies showed that in regions normally 
associated with cognitive generation of affect such as the anterior 
cingulate cortex, the dorsolateral prefrontal cortex, the insula, 
and in the parietal cortex, responders to sleep deprivation 
changed their blood oxygen level–dependent responses (BOLD) to 
emotional stimuli in a pattern opposite to that in nonresponders. 
As an example, the authors found that, for negative stimuli, BOLD 
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activation in the right anterior cingulate cortex was reduced in re-
sponders to wake therapy but increased in non-responders to 
wake therapy. 
The results from neuroimaging studies does not point to a single 
mechanism of action of wake therapy but certainly to a differen-
tial pattern of activity in brain regions according to responder sta-
tus and to resolution of a dysfunctional brain network. The differ-
ential effect of brain functioning in relation to response to wake 
therapy might point towards the existence of different depression 
subtypes with distinctly different underlying psychopathology. 
Animal investigation has shown, in a wake therapy model, that an 
antidepressant-like effect was dependent on astrocyte-depend-
ent adenosine mediated signaling (259). Adenosine builds up in 
the brain with increasing sleep pressure (the need to sleep). Pro-
found changes in neurotransmitter receptor expression has been 
found to happen throughout the brain in sleep deprivation (260) 
and adenosine might be involved in the antidepressant effect of 
sleep deprivation.  
A number of biochemical and hormonal changes in cytokines 
(261), cortisol (262), growth hormone, and thyroid secretion are 
influenced by wake therapy (263). A study of plasma metabolom-
ics in normal controls showed a more than 40 % increase in sero-
tonin, and also  increases in tryptophan and taurine during sleep 
deprivation compared to sleep (264).   
The supposed mechanism of the antidepressant action of bright 
light is given in the bright light study section and summarized in 
the book chapter by Terman et al (265): bright light acts as an 
acute energizer, a circadian rhythm phase shifter with phase di-
rection depending on timing, and impacts on the level of neuro-
transmitters, all of which are important elements in the chronos 
study. Light exposure upon awakening reduces early insomnia 
(difficulty falling asleep), stabilizes irregular sleep patterns, dis-
courages oversleeping and reduces sleep inertia post-awakening. 
Sleep, when taken in a vulnerable phase after wake therapy, such 
as when oversleeping in the morning, can induce a depressive re-
lapse. Morning light therapy and earlier bedtime are thus protec-
tive factors against relapse into depression after wake therapy. 
This is why the regimens used in the chronos protocol deliber-
ately induced a mild form of sleep phase advance on the recovery 
sleep nights and psychoeducated patients on sleep time stabilisa-
tion to avoid oversleeping. The crucial hypothesis in the chronos 
study was not to achieve an antidepressive response to wake 
therapy. This has been shown in a great number of trials. What 
was important was to use chronotherapeutic principles to avoid 
relapse and deterioration between wake therapies on recovery 
nights and in the weeks after the intervention. To be able to 
measure whether this was the case we employed a large number 
of scales and day-to-day assessments in the intervention week. 
 
Methods and materials 
Design of study                                                                                          
The chronos study was designed as a randomised controlled trial 
with rater blinding. Patients were randomised, with a computer 
generated block size of four, into either a wake group or an exer-
cise group. The wake group included wake therapy, sleep phase 
advance and sleep time stabilisation with continuous light ther-
apy. The exercise group included individually tailored daily exer-
cise of moderate intensity for at least 30 minutes. The study was 
divided into four parts (figure 1): a one-week outpatient run-in 
phase, a one-week inpatient intervention phase, a seven-week 
outpatient continuation phase and a 20-week outpatient follow-
up phase. Randomisation took place prior to the run-in phase. 
The exercise group was designed to act as an active control. To 
avoid any placebo response from the inpatients chronotherapeu-
tic interventions we used a design where patients in the exercise 
group were also admitted to open psychiatric wards for the same 
time period. A description of the different treatment elements is 
given below in figure 4.1. 
Figure 4.1 Treatment elements in the chronos study 
 
 
In the one-week outpatient run-in phase all patients were started 
up on 60 mg of duloxetine and self-assessed their mood 7 times a 
day over a consecutive six day period.  
In the one-week intervention phase patients in the wake group 
went through the wake therapy regime including a one week in-
patient intervention with total sleep deprivations on Mondays, 
Wednesdays and Fridays interspersed with recovery sleep nights 
on Tuesdays, Thursdays and Saturdays and these were scheduled 
with an early bedtime (8 pm at latest) and an early rise time (ac-
cording to light therapy timing but at 8 am at the latest) to 
achieve a slight sleep phase advance. Light therapy was used daily 
from the start on Mondays and continued for the whole of the 
study period. Patients randomised to the exercise group started 
daily exercise from Mondays and continued daily for the whole of 
the study period.  
Patients in the wake group were orally informed and given writ-
ten instructions on sleep hygiene, wake therapy, timing and use 
of light therapy.light therapy was started on tuesday morning 
based on an algorithm derived from the scores of the morning-
ness-eveningness questionnaire (MEQ= measuring the level of 
morningness or eveningness  based on preference of tasks and 
sleep timing) as published by Michael Terman (90). Sleep time 
stabilisation was secured, in the wake group, by daily consulta-
tions with the patients at the ward with a focus on giving guid-
ance on how to administer the sleep on the recovery nights and 
sleep on the nights after discharge. Warnings were given, espe-
cially against morning napping due to the propensity for relapse 
induction (230, 266).  
Patients in the exercise group were orally informed and given 
written instructions regarding exercise, contact information for 
their personal physiotherapist, exercise logs, a basic exercise 
manual, and the Borg scale to self-assess degree of exertion. They 
started up on the individual exercise program on Mondays, in-
structed by physiotherapists who were part of the research team. 
13
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No guidance on sleep was given to patients in the exercise group 
and they followed the normal sleep schedule of the ward.  
All patients were discharged on a Saturday and assessed at the re-
search unit on the following Monday. A description of treatment 
elements in the intervention-phase is shown in figure 4.2. 
 
Figure 4.2. Nomenclature and structure of the intervention phase 
 
In the seven-week outpatient continuation-phase all patients 
were kept on an unchanged dosage of 60 mg duloxetine. Patients 
in the wake group continued with daily bright light therapy and 
sleep time stabilisation and patients in the exercise group contin-
ued with daily exercise. Patients were assessed weekly. 
In the 20-week outpatient follow-up phase all therapy elements 
were carried out as in the seven-week continuation-phase. Pa-
tients were assessed every four weeks.  
To attain blinding of assessment, patients were told not to reveal 
group allocation to assessors at rating sessions. Instructors of 
wake therapy, bright light therapy, and exercise were unblinded.  
The study was monitored (GCP unit Copenhagen) and approved 
by the Regional Scientific Ethical Committee, the Danish Medi-
cines Agency and the Danish Data Committee.  
Wake therapy procedures 
On wake nights patients were instructed to stay up the entire 
night and were not to sleep on the following day until 8 pm. Pa-
tients filled in the Stanford Sleepiness Questionnaire (267), for 
every hour on the wake nights. Patients were, during the wake 
period, allowed to walk freely in and outside the ward, to use the 
facilities and were instructed to avoid darkness. The light intensity 
during the wake period was thus ambient evening level. The ward 
staffs was instructed not to press patients to stay awake and pa-
tients were informed that no substantial help could be expected 
from ward personal to stay awake. On recovery nights patients 
were scheduled to go to sleep at 8 pm and to wake up no later 
than 8 am (a milder version of a sleep phase advance). Patients 
were allowed to take a maximum of two additional separate wake 
therapies from week four to seven if they had not attained an ad-
equate response (Hamilton score > 7).  
Light therapy procedures                                                                   
Patients took 30 minutes of light therapy at 4 am on each wake 
nights to alleviate tiredness. Daily morning light therapy was 
started on the morning after the first wake night, and continued 
for the remaining study period (at home). Light was administered 
from a SMIFA Biolamp (colour temperature 5500 K, 10000 lux 
white light at a 40 cm distance from screen), for a duration of 30 
minutes. Timing of light therapy was scheduled from an algorithm 
based on the Morningness-Eveningness Questionnaire (MEQ) 
score, with 7 o’clock in the morning as the earliest, as devised by 
Terman et al (90). 
Sleep time stabilization procedures 
Sleep logs were recorded in both groups but only in the wake 
group were they used to guide patients to keep a stable sleep-
wake cycle and prevent oversleeping. Patients in the wake group 
were encouraged not to go to sleep later than midnight.  
Exercise procedures                                                                                    
The exercise program consisted of a basic exercise program sup-
plemented with any exercise preference of the patients like run-
ning, bicycling or gardening. Patients in this group followed the 
ordinary bedtime and sleep length regime in the open ward and 
exercise was taken between 9 am and 4 pm. At home patients 
could start exercise in the morning as early as they wished, but 
were advised not to exercise later than 7 pm due to the risk of in-
somnia. Patients were seen weekly for the next seven weeks, in 
training group/ individual instruction. At each visit the physiother-
apists evaluated each patient’s exercise performance. This was 
done by inspecting the daily entries in the exercise logs and 
through a questionnaire evaluating, for the preceding week, the 
degree of compliance with the training program (0 = none, 100 = 
complete and >100 more than expected) and the need for sup-
port (ranging from minimal to maximal, score 1-6). The duration 
and type of exercise could be adjusted at all visits according to 
the individual patient’s motivation. Patients were also allowed ex-
tra sessions with the physiotherapist if needed. Training was for 
one hour in a group of three to five patients or individually.  
Medication                                                                                                 
All current antidepressants were discontinued at inclusion. study 
medication was a fixed dosage of 60 mg duloxetine for the first 
nine weeks of the study. in the follow-up period medication could 
be increased or changed if no improvement was seen. anxiolytics 
and hypnotics could be prescribed for the whole study period.  
 
Assessment                                                                                             
Diagnosis of major depression was confirmed at baseline by use 
of the M.I.N.I. instrument (131). Primary interviewer assessment 
scale was the HAM-D17 for the weekly and 4-weeks assessments 
and the HAM-D6 scale for the intervention days. The HAM-D6 
scale does not contain sleep items making it appropriate for wake 
therapy assessments. All patients were furthermore assessed 
with self- assessment depression scales, sleep logs, medication 
logs, light timing logs, exercise logs, side effects scale, and daily 
depression self-assessments with the Preskorn scale (= VAS scor-
ing from 0 = no depression to 10 = worst depression ever) used in 
this thesis to monitor day-to-day depression severity daily for the 
first nine weeks and thereafter every four weeks.  
Primary outcomes as stated in the protocol were response and re-
mission rates after two, nine and 29 weeks of therapy. Response 
rates were defined as a reduction in HAM-D17 baseline scores of 
50 % or more, and remission rates as a HAM-D17 score of less than 
8. 
                                                                            
Results 
The hypotheses stated in the protocol were confirmed. Patients in 
the wake group had an immediately better antidepressant effect 
than patients in the exercise group from the day after the first 
wake therapy as measured on the HAM-D6 scale with response 
rates 58.7 % versus 13.7 (p < 0.0001)  and remission rates 38.6 % 
versus 2.9 % (p < 0.0001). Patients were last assessed on the ward 
after the second recovery sleep (at day 5, having then performed 
the second wake therapy the night before), and response rates 
were then 75.0 % versus 25.1 % (p < 0.0001) and remission rates 
were 56.8 % versus 6.0 % (p < 0.0001) in the wake versus exercise 
groups.  
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Some deterioration in both groups was seen at the next assess-
ment at week two (3 days later) but a statistically significant dif-
ference favouring the wake therapy group was still present on all 
used scales. On the HAM-D17 scale response rates were 41.4 % 
versus 12.8 % (p=0.003) and remission rates were 23.9 % versus 
5.4 % (p=0.004) at week two. Similar results were found on the 
HAM-D6 and MES scales. This better outcome for the wake group 
was sustained for the seven weeks following the intervention 
phase with endpoint (week nine) response rates of 71.4 % versus 
47.3 % (p = 0.04) and endpoint (week nine) remission rates of 
45.6 % versus 23.1 % (p = 0.04). In the follow-up period a continu-
ous improvement was seen in both groups. At end of the follow-
up phase (week 29) response rates were similar between groups 
with 74.6% in the wake versus 64.4% in the exercise group (p = 
0.22). Remission rates were statistically significantly higher in the 
wake group with 61.9% versus 37.9% in the exercise group (p = 
0.01). HAM-D17 endpoint scores were statistically lower in the 
wake group with endpoint scores of 7.5 (SE = 0.9) vs. 10.1 (SE = 
0.9) in the exercise group (p = 0.02).  
In a further analysis from the one-week intervention phase, we 
found that patients in the wake group who had been napping in 
the discharge period (Saturday, Sunday and Monday when dis-
charged from the inpatient ward) had a larger deterioration of 
mood at the next assessment at week two compared to patients 
not napping in the discharge period (p = 0.02). This effect of nap-
ping was not found in the exercise group. Furthermore, patients 
that did nap in the discharge period had a poorer response to the 
first wake therapy compared to patients not napping in this pe-
riod. Probably they were sleepier, not able to resist napping, 
which could also have affected the course of their wake therapy 
(microsleep). Figure 4.4 shows the effect of napping. 
Figure 4. Effect of napping on depression level 
 
The diurnal variation of mood was assessed in the week prior to 
the intervention week, with 7 self-ratings during six days, by the 
Preskorn scale (0 = no depression, 10 = worse depression ever, 
range 0-10). Mood changes over the day ranged from a maximum 
score increase (worsening during the day) of 3.8 point to a 3.6 
points score reduction (improvement during the day). In the wake 
group, a positive diurnal variation (improvement during the day) 
was associated with a better outcome (examined by the HAM-D6), 
after the wake therapies, compared to a negative diurnal varia-
tion (worsening during the day). In the exercise group, the re-
verse was found, as a positive diurnal variation (morning worst) 
was associated with worse outcome compared to a negative diur-
nal variation. This interaction between group and diurnal varia-
tion was statistically significant (p=0.0004).  
Patients in the exercise group performed exercise with a mean of 
63.0 minutes/day (55.3) for the first eight weeks and 41.9 (40.2) 
min/day in the follow-up period.  
Sleep diaries, from the intervention phase, showed that patients 
in the wake group slept a total of 49:45 (6:03) hours: minutes ver-
sus an average of 60: 02 (7:45) hours: minutes in the exercise 
group during the intervention week (excluding naps). Patients in 
the wake group thus lost app. 10 hours of sleep during this week 
relative to the exercise group. The reason that the sleep debt was 
relatively small was due to a partial compensation on the long re-
covery nights. In the wake group patients slept 10:35 (1:11), 
10:14 (1:41), and 9:51 (1:58) hour: minutes on the I and II and III 
recovery night. Patients in the exercise group, on the correspond-
ing nights, slept 7:17 (1:20), and 7:47 (1:35) and7:14 (1:48) hour: 
minutes. This difference between sleep duration for the groups 
was statistically significant for each of the three days (p < 0.0001). 
Sleep diaries, from the continuation phase, show that sleep was 
phase advanced in the wake group compared to the exercise 
group as illustrated by a sleep midpoint in the wake group / exer-
cise group of 3:34 AM (1:41) / 3:28 AM (1:51) at baseline and 3:02 
AM (1:06) / 3:43 AM (1:47) at week nine (wake group p < 0.001; 
exercise group p = 0.08). The day-to-day variation of all sleep pa-
rameters (sleep onset, sleep offset and sleep midpoint) was sig-
nificantly smaller in the wake group compared to the exercise 
group (for sleep midpoint p < 0.01) in the first 9 weeks of the 
study. In the follow-up period the advance of the sleep-wake cy-
cle seen in the continuation phase was only partially maintained 
with sleep onset at 23:19 (SE = 0:05) in the wake group and at 
23:42 (SE = 0:04) in the exercise group and sleep offset at 7:39 (SE 
= 0:07) in the wake group and at 7:37 (SE = 0:06) in the exercise 
group, at week 29. 
At baseline, patients were asked whether they in their current de-
pressive episode had experienced mood drops after day-time 
sleep. This was thought to be a predictor for relapse after wake 
therapy. Data showed that 47.1 % per cent of patients had experi-
enced this phenomenon with a mean duration of the mood drop 
of 92.7 (69.5) minutes with no significant differences between 
groups. This presence of mood drop was associated with higher 
depression scores in the intervention week (p =0.05) without any 
difference between groups.  
During the first 9 weeks of therapy seven patients dropped out of 
the wake group and four patients of the exercise group, in the fol-
low-up phase the dropout was six versus four patients. 
Sensitivity analyses from the follow-up phase showed that the 
continued difference between groups at endpoint was robust and 
that drop-out rates, depression severity at drop-out, time in 
study, and causes for drop-out did not differ across the two 
groups.  
 
Discussion 
The hypotheses stated in the protocol were: “does a chonothera-
peutic intervention yields a greater response and remission rate 
than exercise?”, and ”is daily exercise duration of minimum 30 
minutes attainable in patients with major depression?”, and 
“does diurnal mood variation predict response to wake therapy”, 
all of which was confirmed. 
The primary endpoint, response and remission, showed statisti-
cally and clinically meaningful greater response and remission 
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rates in the wake group, at the end of the intervention-phase, af-
ter the end of the continuation-phase and, regarding remission, 
after end of the follow-up phase. Patients’ completion and com-
pliance with wake therapy procedures, light therapy and exercise 
were good. Patient evaluations from semi-quantitative question-
naires were positive regarding all treatment elements. Wake ther-
apy was however, in a few patients associated with anxiety at-
tacks (four patients). None of neither these nor any other of the 
patients experienced delusions, that have been reported to 
worsen during wake therapy (268), probably due to the exclusion 
of patients with psychotic depression. Even though the proce-
dures were able to successfully avoid relapse between wake ther-
apies, some patients did experience worsening after discharge, 
probably due to being unable to resist napping. One of the possi-
ble adverse effects of our intervention was the use of a dosage of 
bright light late at night, aimed to alleviate tiredness. This might 
have shifted patients’ circadian phase in an unknown direction. 
According to the PRR, light given at the most sensitive phase of 
the circadian system, as we did, using a light pulse at 4 AM, could 
either phase advance or phase delay sleep. If light therapy phase 
delayed sleep this would induce increased sleep inertia when try-
ing to get up in the days after discharge and thus a tendency to 
nap during the day and provoking mood drops. Probably light 
therapy (as a thirty minute 10’000 lux light pulse) during the night 
should be avoided during wake therapy, or rather, to keep pa-
tients more alert, the general lighting intensity throughout the 
whole night could be enhanced to about 500-600 lux. This might 
counteract the sleepiness, and because it is spread across the 
whole night, less phase shifting would be induced.   
Caution should be taken when interpreting how much the individ-
ual patient experienced study procedures as a burden. Clinical tri-
als are an artificial situation in many ways (e.g., researcher enthu-
siasm, patients seeking the “last treatment option”, higher service 
level during study period) and the real balance between treat-
ments will only show itself in daily clinical practice. We do believe 
that the procedures in both the treatment groups in the chronos 
study required a substantial investment from a depressed patient 
and also required careful consideration and support from clini-
cians and staff.  
Hamilton scores of 9.0 (SE=0.8) at week 9 and 7.5 (SE=0.9) at 
week 29 in the wake group, and 12.0 (SE=0.8) at week 9 and 10.1 
(SE=0.9) at week 29 in the exercise group are very close to remis-
sion. Why did patients in both groups respond so well to treat-
ment? The substantial effort that we put into sleep regulation and 
sleep guidance in the wake group possible helped. At least re-
search data seems to support that restriction of napping in day-
time is beneficial as napping has a significant impact on ther-
moregulatory processes linked to sleep inertia (269) and, as our 
data has shown, napping induced mood drops in a high percent-
age of the patients. As recent studies have found exercise to have 
an effect on depression, the exercise probably did act as an active 
intervention. This means that the “true” effect of the chronother-
apeutic intervention, in this study, is under-evaluated. 
The hierarchy of treatment options for a depressed patient is by 
no means clear and depends on patient and illness characteristics, 
level of psychiatric service and skills, and previous experiences of 
the individual clinician. The use of a wake therapy regimen in its 
current form should be restricted to centres with special interest 
and experience in chronotherapeutics. These centres should build 
up a database collecting predictors of response in order to tune in 
on which patients to offer this kind of treatment. Table 4.5 shows 
a comparison of RCT studies using wake therapy in combination 
with other chronotherapeutic methods and/ antidepressants. 
Both design and study period vary considerably between studies 
making comparisons very difficult.  
 
Table 4.5. Comparison of studies using wake therapy with drugs 
or other chronotherapeutic methods.  
Author 
 
Hols-
boer-
Trachs-
ler  
1994 
 (209) 
Kuhsl             
1996 
(210) 
Neum
eister 
1996 
(232) 
Smeral
di 
1999 
(231) 
Wu                    
2009 
(204) 
Mar-
tiny           
2012 
(270) 
Type Bi- and       
unipolar 
Bi-and 
uniplar 
Bi- and      
uniplar 
Bipolar Bipolar Bi- and                    
unipo-
lar 
Setting Inpt. Inpt. Inpt. Inpt. Outp Outpt                    
Design RCT RCT RCT RCT RCT  RCT  
Blinding No info. None Rater 
blind 
Double 
blind 
None Rater 
blind 
AD  Tri-
mipra-
mine 
Amitrip-
tyline  
Contin-
ued AD 
None Ser-
traline/
other 
Dulo- 
xetin  
Active 
inter-
vention 
AD + BL 
or 
AD + 
Wake 
 
 
PSD+AD PSD re-
spond-
ers: BL 
+ AD 
Wake + 
active 
pindolol 
Wake + 
SPA + 
BL + AD 
+ MS 
AD + 
wake + 
BL + 
SPA 
Wake 
type 
PSD 
01:30 
AM 
PSD 
01:30 
AM 
PSD 
01:30 
AM 
TSD TSD TSD 
Nb. of 
wakes 
6 6 1 3 1 3 (+2) 
Days 
betw. 
wakes 
1 and 6 4-5 - 1 - 1 
Control 
inter-
vention 
AD AD PSD re-
sponse: 
DL + 
AD 
Wake + 
placebo 
pindolol 
AD +MS  AD + 
Exer-
cise 
Dur. 42 d 4  w  7 d 10 d 7 w 29 w 
Nb. Pt. 42 51 20 40 49 75 
Scale HDRS 
17 
HDRS 
21 
HDRS 
21 
HDRS 
21 
HDRS 
19 
HDRS 
17 
Result 
 
Negative Positive Positive Positive Positive Posi-
tive 
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AD = antidepressants, MS = mood stabilizer, HDRS = Hamilton depression 
rating scale, MADRS = Montgomery Åsberg Depression Rating Scale, SPA = 
sleep phase advance, TSD = total sleep deprivation, PSD = partial sleep 
deprivation, BL = bright light, DL = dim light, w= week, d = day. 
 
5. General conclusion                                                                           
General results 
In the bright light study, the PEMF study and the chronos study 
we found an accelerating effect of the active interventions and a 
larger reduction in depression severity at endpoint. 
In the Pindolol study the main outcome showed no difference be-
tween groups. Analysis pre-specified in the protocol as a second-
ary outcome showed an interaction between metabolizer status 
of venlafaxin and the effect of pindolol on depression scores.  
Table 5.1 shows the trial designs of all four studies. All studies are 
RCTs with control groups using placebo or sham treatment or an 
alternative treatment. Study length varied from 19 days to 29 
weeks. All primary outcomes were based on scores from the 
Hamilton Depression Rating Scale.  
Table 5.2 shows common sociodemographic data from al studies. 
Age was comparable between studies, and numerically a little 
higher in the PEMF study. A higher percentage of females was 
seen in all studies. The duration of the current depressive episode 
was long, from 12.0 (15.8) months to 34.7 (55.0) month. The large 
SD values of illness duration illustrate that the distribution of ill-
ness length is highly skewed due to outliers. This is a common 
phenomenon caused by some patients having suffered from de-
pression for decades. The number of previous depressive epi-
sodes was between 1.5 (2.0) and 8.7 (11.0) and somewhat higher 
in the PEMF and chronos studies. A major part of the patients 
were in antidepressant treatment at inclusion. Percentages of bi-
polar patients were low in all studies. 
Table 5.3a shows baseline depression levels as measured on the 
HAM-D17, HAM-D6, MES, SIGHSAD, and WHO-5. Severity varies 
with scores from 20.9 (3.3) to 24.3 (5.4), corresponding to moder-
ate depression (18 < HAM-D17 < 24). Values were numerically but 
statistically insignificantly higher in intervention groups.  
Table 5.3b shows endpoint scores on the HAM-D17, HAM-D6, 
MES, SIGHSAD, and WHO-5 scales.  
Endpoint scores in the active groups of the light and chronos 
studies approached remission both on the HAM-D17 (<8) and the 
HAM-D6 (<4) after five, nine and 29 weeks. In the chromos study 
the WHO-5 score at week 29 was within the normal level of the 
general Danish population (271, 272).  
Table 5.4 shows response and remission rates at endpoint on the 
HAM-D17 scale. Response rates in the active groups vary from 
41.4 % to 74.6 % and in the placebo groups from 12.8 % to 64.4 
%. 
Remission rates in the active groups vary from 14.1 % to 61.9 % 
and in the placebo groups from 4.1 % to 37.9 %.  
Table 5.5 shows effect sizes, based on Cohen’s d, with values be-
tween 0.39 and 0.87 (moderate-high effect size) on the HAM-D17, 
between 0.45 and 0.91 on the HAM-D6, and between 0.49 and 
1.06 on the MES. 
The outcomes scales, used in the included studies in this thesis, 
have been shown to have very high interrater reliability with in-
tra-class coefficients of 0.93 (HAM-D17), 0.89 (HAM-D6), and 0.91 
(MES) (273). 
Side effects were measured by use of the UKU scale. Specific 
items were selected from the full UKU instrument for the differ-
ent studies according to expected side effects from the psycho-
tropic drugs used. Expected or suspected side effects of augmen-
tation methods were also recorded, as were any adverse events. 
The UKU instrument contains side effects items categorized as 
psychiatric, neurological, autonomic and miscellaneous. In the 
four studies we used the following items: 
Psychiatric = concentration, sedation, memory disturbance, inner 
tension, increased sleep, reduced sleep, increased dreaming, 
nightmares (pindolol study), emotional indifference. 
Neurological = tremor, paresthesia 
Autonomic = reduced salivation, nausea, diarrhoea, constipation, 
voiding problems, orthostatic hypotension, palpitations, in-
creased sweating, cold extremities (pindolol study) 
Miscellaneous = weight gain, reduced sexual libido, erective dys-
function, orgasmic dysfunction, headache, irritation of the eyes 
(light study) 
Items were scored according to the manual as: score 0, no side-
effects; score 1, mild side-effects that do not interfere with the 
patient’s performance; score 2, side-effects that interfere moder-
ately with the patient’s performance; score 3, side-effects that in-
terfere markedly with the patient’s performance. 
In the bright light study we published side effects as “treatment 
emergent side effects” defined as side effects that increased from 
baseline at some time point during the study duration. These 
were nausea/vomiting (both groups), diarrhoea (both groups), 
headache (both groups) and eye irritation (bright light group). All 
side effects were rated as mild and did not interfere with daily 
life. The rest of the rated UKU items were either unchanged or re-
duced from baseline.  
In the pindolol study the rated UKU item scores were moderate 
with decreasing scores from baseline and without significant dif-
ferences between groups. A larger reduction from baseline of the 
items tenseness/nervousness and impaired memory were seen in 
the in the placebo group compared to the pindolol group.  
In the PEMF study we published “treatment emergent side ef-
fects” and reported those UKU items where the number of pa-
tients with treatment emergent side effects in the active PEMF 
group was double the number of patients in the sham group who 
developed symptoms. This was the case for increased dream ac-
tivity, suicidal ideation, tremor, paresthesia, dizziness, constipa-
tion, stranguria/voiding problems, increased sweating, helmet felt 
heavy, flu-like symptoms, lower back pain, stabbing pain in the 
head. The number of patients in the active PEMF group experi-
encing treatment emergent side effects was below 3 for any side 
effect. One patient receiving active PEMF treatment developed 
mild suicidal ideation lasting for two days due to a social incident. 
No intervention was necessary and the patient continued in the 
study. 
In the chronos study side effects reached a maximum of 2 or less, 
corresponding to a moderate interference with daily activities in 
both groups. Four patients developed anxiety attacks related to 
wake therapy. One patient with insulin dependent diabetes devel-
oped hypoglycaemia during a wake therapy night, which was re-
lieved by administration of oral glucose. One patient experienced 
watering eyes due to light therapy and one patient developed 
substantial pain in the Achilles tendon due to exercise. Blood 
pressure and weight were unchanged from baseline to endpoint 
(nine weeks).  
General discussion           
All augmentation strategies were well tolerated and except for 
the pindolol study active groups were superior to placebo/sham 
interventions. The proposed mechanism of action of the antide-
pressant augmentation involves a variety of systems: gene ex-
pression of circadian clocks, internal and external circadian 
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rhythms entrainment and synchronisation, sleep time stabilisa-
tion and changes to sleep architecture, direct sensory stimulation 
from retinal receptors to a variety of changes in brain areas in-
cluding the limbic system, autoreceptor blockage or desensitisa-
tion (pindolol and wake therapy), electrical stimulation of hypoth-
esized electrical neural sensors, activation of intracellular second 
messengers, regulation of brain stem nuclei and resultant 
changes in neurotransmitters.  
There is no obvious final common pathway that can be deduced 
from these mechanisms of action. The psychopathology of de-
pression points to that depressive illness involves a multitude of 
cortical, subcortical and brainstem dysfunctions, presenting clini-
cally as changes in mood, anhedonia, loss of appetite, loss of sex-
ual interest, reduced concentration, sleep disturbances and many 
other symptoms and signs. Therefore it is not surprising that anti-
depressant agents can work through targeting different areas of 
the brain and working on different parts of the neural machinery.  
In the three studies where the active treatment was superior to 
control treatment, patients had a reduction in HAM-D17 / HAM-D6 
scores from a baseline range of 21.4-24.3 / 12.6-13.1 (moder-
ate/severe depression) to an endpoint range of 7.5-11.0 / 4.1-6.7 
(questionable to mild depression). Response rates in the three 
studies reached a range of 72.9 % - 74.6 % and remission rates 
33.9 % - 61.9 %. The studies thus show that it is possible to aug-
ment the effect of antidepressant treatment and with a clinically 
meaningful magnitude.  
The four studies are very different in their set-up and from an ad-
ministrative and economical viewpoint light therapy is the easiest 
and most cost-effective modality. PEMF requires rather expensive 
equipment, but once this is purchased, it is viable for years. The 
latest PEMF study used home treatment, making it much easier to 
administer (186). The chronos study is the most labour intensive 
study to carry out primarily due to safety precautions for the 
wake therapy. However, as no serious adverse events appeared in 
the study due to wake procedures and as a there are now several 
rapports of successful home-treatments with wake therapy (219), 
this treatment can probably be administered in a more cost-effec-
tive way, at least for some of the patients. The chronos study en-
compasses as an important part, a high degree of psychoeduca-
tion on sleep, and this is readily useful. Caution should however 
be taken as we do not know to what extent the sleep stabilisation 
was effective compared to the other elements in the chronos 
study.        
 
Table 5.1 Design of studies 
Study Design Experimen-
tal 
interven-
tion 
Control in-
tervention 
Dura-
tion 
Primary out-
come 
and scale 
Light  RCT Bright white light 
Dim red 
light 9 weeks 
Improvement 
HAM-D17 
Pindo-
lol  RCT 
Active pin-
dolol and 
active ven-
lafaxine 
Placebo 
pindolol 
and active 
venlafax-
ine 
19 days Response rate HAM-D17 
PEMF RCT 
Active 
PEMF sti-
mulation 
Sham 
PEMF sti-
mulation 
5 weeks Improvement HAM-D17 
Chro-
nos RCT 
Wake ther-
apy, sleep 
Exercise 
and dulo-
xetine 
29 
weeks 
Response 
/ Remisson 
rates 
time stabili-
sation, 
bright light 
therapy, 
duloxetine 
HAM-D17 
 
Table 5.2 Sociodemographics 
Parameter Group Light Pindolol Pemf Chronos 
Age, years, mean 
(SD) Active 
43.1 
(15.8) 
48.5 
(15.7) 
56.4 
(13.7) 
46.9 
(12.6) 
Cont-
rol 
45.9 
(16.1) 
45.3 
(13.7) 
49.7 
(11.4) 
48.5 
(11.2) 
Female gender, per 
cent 
Active 70.8 % 60.0 % 68.0 % 64.9 % 
Cont-
rol 66.7 % 31.3 % 72.0 % 52.6 % 
Duration of present  
Depressive episode, 
Month, mean (SD) 
Active 
12.0 
 (3-24)* 
12.0 
(15.8) 
31.3 
(34.3) 
24.9 
(29.0) 
Cont-
rol 
10.0 
 (3-24)* 
18.8 
(14.3) 
34.7 
(55.0) 
21.3 
(54.3) 
Mean number of de-
pressive 
episodes in lifetime 
(SD) 
Active 3.7 (5.9) 2.3 (4.3) 6.4 (5.3) 8.7 (11.0) 
Cont-
rol 4.3 (6.3) 1.5 (2.0) 6.4 (5.5) 6.2 (7.5) 
Antidepressant 
treatment 
at inclusion, per cent 
Active 45.8 % 53.3 % 100 % 83.4 % 
Cont-
rol 29.6 % 57.1 % 100 % 84.2 % 
Patients with bipolar 
Disorder, per cent 
Active 2.3 % 6.7 % 8.0 % 16.2 % 
Cont-
rol 0 % 6.3 % 0 % 15.8 % 
* Median with 25th and 75th quartiles 
 
Table 5.3a Baseline depression severity 
Group / scale Light 
(SD) 
 
Pindolol 
(SD) 
Pemf 
(SD) 
Chronos 
(SD) 
Active 
Ham-D17 
22.4 
(4.4) 
24.3 
(5.4) 
21.1 
(4.1) 
23.9 
(4.3) 
Control 
Ham-D17 
22.1 
(3.5) 
23.4 
(4.8) 
20.9 
(3.3) 
22.3 
(3.8) 
Active 
Ham-D6  
12.6 
(1.9) 
13.1 
(2.5) 
12.6 
(2.1) 
13.1 
(1.7) 
Control 
Ham-D6 
11.7 
(1.4) 
12.3 
(2.3) 
12.1 
(2.1) 
12.6 
(2.0) 
Active  
MES 
21.6 
(3.5) 
23.7 
(4.0) 
21.6 
(3.0) 
24.1 
(3.4) 
Control 
MES 
20.9 
(2.9) 
22.8 
(3.7) 
21.0 
(2.7) 
22.6 
(3.3) 
 
Table 5.3b Endpoint depression severity 
Group / 
Scale 
Light 
W 5 
(SD) 
Pindo-
lol 
Day 19 
(SD) 
Pemf 
W 5 
(SD) 
Chro-
nos 
W 9 
(SE) 
Chro-
nos 
W 29 
(SE) 
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Active 
Ham-D17  
9.0 
(4.4) 
14.2 
(5.9) 
11.0 
(5.7) 
9.0 
(0.7) 
7.5 
(0.9) 
Control 
Ham-D17 
11.6 
(4.3) 
12.0 
(5.8) 
16.0 
5.6) 
12.0 
(0.8) 
10.1 
(0.9) 
Active 
Ham-D6  
5.5 
(2.8) 
8.4 
(3.4) 
6.7 
(3.7) 
5.1 
(0.5) 
4.2 
(0.6) 
Control 
Ham-D6 
7.0 
(2.6) 
6.8 
(3.7) 
9.8 
(3.7) 
7.3 
(0.5) 
5.8 
(0.5) 
Active  
MES 
10.2 
(5.0) 
15.1 
(6.1) 
11.5 
(5.6) 
10.0 
(0.9) 
7.5 
(1.0) 
Control 
MES 
12.2 
(4.4) 
12.1 
(6.0) 
16.9 
(5.6) 
12.5 
(0.9) 
10.6 
(0.9) 
W =weeks 
 
Table 5.4 Response and remission rates at endpoint on the Ham-
D17 scale with remission defined as a score below 8 and re-
sponse at a 50 % or larger reduction from baseline.  
Group 
 
Light 
W 
 5 
Pindo-
lol 
Day 
 19 
Pemf 
W 
 5 
Chro-
nos 
W 
9 
Chronos 
 W  
 29 
Active  
Resp 
 
66.7 % 52.4 % 61.0 
% 
71.4 % 74.6 % 
Control  
Resp 
 
40.7 % 39.7 % 12.9 
% 
47.3 % 64.4 % 
Active 
Remis 
 
41.7 % 14.1 % 33.9 
% 
45.6 % 61.9 % 
Control 
Remis 
 
14.8 % 28.7 % 4.1 % 23.1 % 37.9 % 
W = weeks, Resp = response, Remis = remission, Light therapy 
study used available data at week five and LOCF at week nine. The 
pindolol, pemf and chronos study used estimated scores.  
 
Table 5.5 Cohen’s unbiased effect sizes at endpoint using LOCF.  
The interval between 0.00 and 0.19 refers to no effect; 0.20 and 
0.39 refers to a small effect; the interval between 0.40 and 0.69 
refers to a medium effect; the level of 0.70 or higher refers to a 
large effect. 
Scale Light 
  W 5 
 
Pindolol 
Day  19 
 
Pemf 
W 5 
 
Chronos 
W 9 
 
Chronos 
W 29 
 
Ham-
D17  
0.45 
 
Na 0.87 
 
0.39 
 
0.13 
 
Ham- 
D6  
0.66 
 
Na 0.91 
 
0.45 
 
0.18 
 
MES 0.49 
 
Na 1.06 
 
0.49 
 
0.18 
 
W = weeks 
6. Future directions 
Only a fraction of the activity in the brain is assessable to con-
scious experience. Thus, probably only a fraction of the underly-
ing psychopathology of depressive illness will translate into dis-
cernable and valid clinical symptoms. The total biology of the 
disorder is thus not available for research based solely on psycho-
metric evaluation. Furthermore, assessable symptoms fluctuate 
rapidly from hour-to-hour and from day-to-day. Rating scales 
gives us is a point-in-time measurement of surfacing symptoms of 
the disorder. However, as the rating scales used in this thesis 
have been constructed using expert clinical global assessments as 
an external validator, and because the used items operate in a 
way fulfilling Rasch criteria (item-response theory), the sum score 
of the scales are a sufficient statistic of the severity of the clinical 
condition (274). Thus, we cannot regard the use of rating scales 
as reductionistic. The rating scales used in the four studies in this 
thesis are excellent to assess present state severity and response 
to treatment and in this way paves the way for new treatment 
methods by correctly establishing true efficacy. 
The shortcoming of rating scales is that it does not automatically 
lead to the underlying biological dysfunction. Therefore we need 
to supplement rating scales with other approaches. 
In response to the recent release of the DSM-5, the director of 
NIMH, Thomas Insel, stressed that future developments in diag-
nostics (and treatment development) must go from a purely 
symptom based system to include genetics, imaging, biomarkers, 
quantifiable psychopathology (retardation, diurnal variation, 
sleep) and cognitive science. This is named the Research Domain 
Criteria (RDoC) and is a research framework aiming at creating a 
new classification and new ways of studying mental illness.  RDoC 
has dysfunction in basic brain mechanisms as the primary focus 
and studies these to understand symptoms across multiple disor-
ders, rather than starting with clinical symptoms and working 
backwards. The defined Domains of functioning are organised in a 
matrix with: negative valence systems (aversive motivation), posi-
tive valence systems, cognitive systems, systems for social pro-
cesses, and arousal/regulatory systems (including sleep and circa-
dian systems), as rows, and as columns different classes of 
variables (or units of analysis) used to study the domains/con-
structs: genes, molecules, cells, neural circuits, physiology (e.g. 
cortisol, heart rate, startle reflex), behaviours, and self-reports, 
(275).  
If this approach is used it becomes clear that the term clinical 
study will have a new meaning, as symptom clusters are not the 
primary focus. The problem of whom to investigate then arises. 
We still need to select study subjects and in the near future we 
will have to rely on the available diagnostic categories, possibly 
extending RDoC approach to healthy family relations or relying 
more on larger control groups (276).  
In some Domains of functioning we do have specific knowledge of 
basic brain dysfunction, and this is the case for major parts of 
chronobiology where internal desynchronisation has been estab-
lished between a number of markers (temperature, blood pres-
sure) and hormones (growth hormone, thyroid hormones, mela-
tonine) and external desynchronisation between the sleep-wake 
cycle and astronomical day-night. Thus, the existence of a PRC for 
light is an example of a domain (circadian systems) that can be in-
vestigated through circadian markers, e.g. melatonin (physiology). 
The circadian system is readily assessable through activity moni-
toring, hormone measurements, sleep recordings.  
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This approach is used in our actual research project (SAFE II) using 
psychoeducation and electronic monitoring of patients with de-
pression discharged from hospital, in order to stabilize the sleep-
wake cycle, prevent oversleeping to prevent relapse, and using 
melatonine profiles (DLMO) and actimetry as biological validators. 
In another study, we are examining diurnal variation of mood 
(negative valence systems) in relation to changes in brain function 
through fMRI (neural circuits). The aim is to find the mechanism 
in the brain responsible for acute changes in mood as seen in 
wake therapy but without the strain of staying awake for ex-
tended periods.  
Another RDoC approach would be to investigate biological 
changes when applying methods that have already been shown to 
have an antidepressant effect such as antidepressant drugs or 
psychotherapy. This will lead to a better understanding of the 
mechanism of action of antidepressant methods.  
 Outside the scope of the RDoC approach we are focusing on the 
living conditions of patients who develop depression and people 
in general. Depression is a disease highly susceptible to environ-
mental stressors (277) and modulation of factors in daily living 
might prevent depression, reduce severity of actual depressive 
episodes, improve treatment of a depressive episode, and reduce 
relapse or recurrence of depression. One possibility is to focus on 
known antidepressant agents such as exercise and lighting condi-
tions. Home mapping could be a new investigational and treat-
ment tool to advice patients on living conditions regarding ambi-
ent luminance, sleep, daily exercise, but also researching the 
impact of food, and social contact on depression. By inviting re-
searchers into their homes, patients might be able to present us 
with a lot of new information on the development and treatment 
of depression. Electronic monitoring is a way to gain real-time as-
sessments of psychopathology and behavior. Electronic monitor-
ing is an area with a great potential and will be incorporated in 
our future studies (278).  
Furthermore the optimisation of lighting conditions in psychiatric 
wards is an area should be subjected to more research. In the 
program Light in Mental health we are initiating randomized trials 
to investigate the effect of optimising spectral composition and 
dynamic intensity of ambient light in affective disorders wards. 
Through the use of fMRI, assessing the function of the serotonin 
system, we hope to be able to optimize spectral composition of 
light to maximum effect on the entrainment of the sleep-wake cy-
cle and antidepressant activity. Finally, the use of simultaneous 
multiple treatment modalities as in the chronos study combining 
several antidepressant treatment methods should be encouraged 
especially in treatment resistant patients. An example of this is 
found in the study by Krstić et al (279) applying TMS in combina-
tion with wake therapy in treatment resistant depression with 
good long-term results. 
Through gradually improvement of individual treatment methods, 
the combination of these, and enhanced collaboration with pa-
tients, we will be able to help more attain remission and recovery.  
 
Conclusion 
PEMF, bright light therapy alone, and wake therapy in combina-
tion with bright light therapy plus sleep time stabilisation were 
able to augment antidepressant drug effect. The augmentation 
was clinically relevant regarding score reductions, response and 
remission rates. Effect sizes were moderate for bright light treat-
ment, moderate for chronotherapy, and large for PEMF. Pindolol 
did not augment the effect of venlafaxine. A statistical significant 
interaction was found between metabolizer status and treatment 
group as a secondary outcome measure.  
Applicability was good for all studies, with low drop-out rates and 
low side effect profiles. Exercise was also found to be applicable 
for patients with depression. These methods should be consid-
ered for use in daily clinical settings. 
The results from the Chronos study should guide us towards a 
deeper understanding of the relation between sleep and depres-
sion and a possibility of developing new drugs that will give a 
more rapid and complete antidepressant effect. 
7. Summary 
Hypothesis 
The hypotheses of all the four included studies share the common 
idea that it is possible to augment the effect of antidepressant 
drug treatment by applying different interventions and with each 
intervention attain a clinically meaningful better effect compared 
to a control condition, and with minor side effects, thus improv-
ing the short- and medium-term outcome in major depression. 
 
Procedures 
Study design 
The basic study design has been the double blind randomised 
controlled trial (RCT).  
In the light therapy study, all patients were treated with sertraline 
for the whole of the study duration. In the first five weeks of the 
study, patients were randomised to treatment with either 60 
minutes of bright white or 30 minutes of dim red light (sham con-
dition). In the four weeks follow-up period, patients were treated 
with sertraline alone.  
In the Pindolol study, all patients were treated with venlafaxine 
and randomised to augmentation with either active or placebo 
matching pindolol tablets.  
In the PEMF study patients were continued on ongoing medica-
tion and randomised to augmentation with active or inactive 
(sham) 30 minutes daily PEMF treatment on weekdays.  
In the Chronos study all patients were treated with duloxetine 
and randomized to either a combination of three wake therapies 
with daily bright light treatment and sleep time stabilisation 
(wake group) or to daily exercise of minimum 30 minutes as an 
active control intervention (exercise group). The Chronos study 
was divided into: (1) a one-week run-in phase where duloxetine 
were started (and continued for the whole 29 week study period), 
(2) a one-week inpatient intervention phase where patient in the 
wake group did three wake therapies (sleep abstinence for the 
whole night and the following day until evening) in combination 
with daily light therapy and guidance on sleep time stabilisation 
and patients in the exercise group started a daily exercise pro-
gram, (3) a seven week continuation phase where patient in the 
wake group continued light therapy and sleep time stabilisation 
and patients in the exercise group continued an individual exer-
cise program, and (4) a 20 week follow-up phase with the same 
treatment elements but where duloxetine dosage could be ad-
justed or changed to other antidepressants.  
 
Recruitment 
Patients recruited for these studies were allocated from general 
practitioners, psychiatric specialist practices and for the lesser 
part from open psychiatric wards. Only a few patients were re-
cruited through advertisements (in the PEMF and Chronos stud-
ies).  
 
 DANISH MEDICAL JOURNAL   22 
Inclusion criteria 
Inclusion criteria were major depression according to the DSM-IV, 
including a depressive episode as part of a bipolar disorder. For 
the PEMF study, treatment resistance was a specific inclusion cri-
terion. 
 
Duration of studies 
Study duration was nine weeks for the light therapy study, 19 
days for the Pindolol study, five weeks for the PEMF study, and 29 
weeks for the Chronos study.  
 
Assessments 
In all studies, assessments were done with clinician rated scales, 
patient self-assessment scales, including quality of life scales and 
a side effect scale. As clinician rated scales we used the Hamilton 
depression rating scale: the HAM-D17 and its 6 item subscale: the 
HAM-D6, the Bech Rafaelsen Melancholia scale (MES), and the 
Bech Rafaelsen Mania scale (MAS). As self-assessment scales we 
used the Major Depression Inventory (MDI), the Symptom Check-
list (SCL-92), and the Preskorn scale. For side effects we used the 
UKU scale. Further scales used are mentioned in the specific study 
sections. Assessments in the light therapy study were done 
weekly for the first six weeks and finally after nine weeks; at four 
time points in the Pindolol study (baseline, days 6, 11 and 19), 
weekly for five weeks in the PEMF study and weekly for the first 
nine weeks of the Chronos study and thereafter every four weeks. 
The clinical setting for evaluation has been the Psychiatric Re-
search Unit at Mental Health Centre North Zealand. For the Bright 
Light study, Pindolol and PEMF study patients were also seen at a 
psychiatric specialist practice in Copenhagen.  
 
Biochemical measures 
In the Light therapy study saliva cortisol was collected at baseline 
before start of light therapy and sertraline and blood was drawn 
for thyroid analysis. In the Chronos study saliva and 24 hour urine 
cortisol was collected in the patients randomised to the exercise 
group. 
 
Main results 
The main results from the Bright Light study covering the first five 
weeks of the study are given in the PhD thesis “Adjunctive bright 
light in nonseasonal major depression” defended and awarded on 
the 18 November 2004 at the University of Copenhagen. Results 
from the cortisol measurement and for the four weeks extension 
period were published in separate papers after the PhD thesis 
and are included in this thesis. 
 
Results from the Bright Light study 
Analysis of the saliva cortisol measurements taken at baseline of 
the study as cortisol awakening profiles (CAR) showed that pa-
tients responded differentially to light treatment according to 
their CAR levels (dichotomized to high or low about the mean). 
Thus, in the bright light group HAM-D17 scores were reduced by 
15.7 (4.2) points for patients with a low CAR (below mean), and 
11.4 (4.8) points for patients with a high CAR (above mean). In the 
dim light group the corresponding values were 11.1 (5.2) for pa-
tients with a low CAR and 11.3 (5.3) for patients with a high CAR.  
This interaction between CAR and treatment group was statisti-
cally significant (p = 0.006).    
Survival analysis, for the first five weeks of the study period, 
showed a statistically significant higher response rate (χ2= 9.6, p 
=0.002) and higher remission rate (χ2 = 12.5, p = 0.0004) for the 
bright light treated group versus the dim light treated group. At 
end of the five weeks of light treatment response rates were 
66.7% versus 40.7 % and remission rates were 41.7 % versus 14.8 
% for the bright versus dim light treated group. In the subsequent 
publication that covered the four weeks extension period where 
light treatment was discontinued, data showed that the attained 
differences in response and remission rates between groups were 
not sustained. The offset of effect was nearly complete after four 
weeks of continued treatment on sertraline only. Thus, at end-
point, response rates were 79.2 % versus 75.9 % and remission 
rates were 60 .4 % versus 55.6% in the bright versus dim light 
groups. The conclusion reached was that bright light in non-sea-
sonal depression should be used to achieve an earlier antidepres-
sant response and that light therapy probably should be of longer 
duration.  
 
Results from the Pindolol study 
The results from the Pindolol study showed that pindolol did not 
augment the effect of venlafaxine for the whole sample. How-
ever, for those patients classified as slow metabolizers, based on 
their O-desmethylvenlafaxine/venlafaxine ratio (ODV/V), pindolol 
did augment the antidepressant effect. For patients classified as 
fast metabolizers, pindolol worsened the outcome. This interac-
tion between ODV/V ratio and treatment group was statistically 
significant (p = 0.01).  
 
Results from the PEMF study 
The results from the PEMF Study showed that treatment with ac-
tive versus sham PEMF augmented the effect of the ongoing anti-
depressant medication treatment. Thus, patients in the active 
PEMF group attained a statistically significant greater score reduc-
tion from week one and at all subsequent assessments compared 
to the sham treated group (p < 0.01). Response and remission 
rates in the active PEMF group were also larger than in the sham 
treated group with response rates at endpoint of 61.0 % versus 
12.9 % (p < 0.01) and remission rates of 33.9 % versus 4.1 % (p < 
0.05).  
 
Results from the Chronos study 
The Chronos study, published in three papers, covers a one-week 
intervention phase, a seven weeks continuation phase, and a 20 
weeks follow-up phase.  
Results from the intervention week showed that patient treated 
in the wake group, from the day after the first wake therapy, had 
en clinically and statistically significant better antidepressant ef-
fect compared to the exercise group. On the HAM-D6 scale (which 
does not contains sleep items), patients in the wake group had a 
response rate after the first wake therapy of 58.7% versus 13.7% i 
the exercise group (p <0.0001) and a remission rate of 38.6% ver-
sus 2.9% (p <0.0001). After the second recovery sleep (the night 
after the second wake therapy = dag 5) patients in the wake 
group had a response rate of 75.0% versus 25.1% in the exercise 
group (p <0.0001) and remission rates of 58.6% versus 6.0% (p 
<0.0001). 
Results from the continuation phase showed, on the HAM-D17 
scale which was used at all the follwing assessments, at week two 
response rates of 41.4% in the wake group and 12.8% in the exer-
cise group (p = 0.003) and remission rates of 23.9% versus 5.4% (p 
= 0,004). This clinically relevant and statistically significant differ-
ence between the wake and exercise groups was maintained at 
all the subsequent assessments with response rates of 71.4% ver-
sus 47.3% (p = 0.04) and remission rates of 45.6% versus 23.1% (p 
= 0.04), at week nine. 
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Results from the 20 weeks follow-up phase showed a continued 
better effect in the wake group at all visits with HAM-D17 depres-
sion scored at week 29 of 7.5 (SE = 0.9) in the wake group versus 
10.1 (SE = 0.9), (p = 0.02) in the exercise group. Remission rates 
were higher in the wake group with endpoint rates of 61.9% ver-
sus 37.9% (p = 0.01) in the exercise group. Response rates was 
only numerically, but not statistically, higher in the wake group 
with 74.6% versus 64.4% in the exercise group (p = 0.22). 
The sleep diary data showed a statistically smaller day-to-day var-
iation in sleep onset, sleep midpoint, sleep offset and sleep dura-
tion in the wake group compared to the exercise group as a sign 
of better day-to-day sleep-wake cycle control in the wake group 
(p < 0.01). In the first nine weeks of the study patients in the 
wake group had a moderate sleep phase advance that diminished 
during the follow-up period. 
The hypothesised predictors for response to wake therapy were 
confirmed. Thus, in the wake group, a positive diurnal variation 
(morning worst, evening best) was associated with a better out-
come, after the wake therapies, compared to a negative diurnal 
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